

1. A compound of formula (I)




(I),

or a pharmaceutically acceptable salt thereof, wherein


A is




(i), (ii), (iii), (iv), (v)




(vi), (vii), (viii), (ix)



(x), (xi), (xii), (xiii)



(xiv), (xv), (xvi), (xvii) or



(xviii);

R_1 is hydrogen or R_aR_bN;

R_2 is hydrogen, alkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, heterocyclecarbonyl or R_eR_fN-alkyl–C(O)-;

R_3 is alkyl, alkoxy, aryl, cyano, cycloalkyl, halogen, haloalkyl, heteroaryl, nitro, or R_gR_hN-;

R_4 is alkyl, alkoxyalkyl, aryl, cycloalkyl, heteroaryl, heterocycle, heterocyclealkyl, R_jR_kN- or R_jR_kN-alkyl-;

R_5 is alkyl, aryl, or heteroaryl;

R_6 is alkyl, alkoxyalkyl, R_jR_kN-alkyl-, aryl, cycloalkyl or heteroaryl;

R_7 is alkyl, aryl or heteroaryl;

R_a and R_b are each hydrogen;

R_e and R_f are each independently hydrogen, alkyl, arylalkyl, heteroarylalkyl, R_6-C(O)-, or R_7-$S(O)_2$-;

R_g and R_h are each independently hydrogen, alkyl, or alkylcarbonyl;

R_j and R_k are each independently hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl, or heterocycle;

R_i, R_{ii}, R_{iii}, R_{iv}, R_v, R_{vi}, R_{vii}, R_{viii}, R_{ix}, R_x, R_{xi}, R_{xii}, R_{xiii}, R_{xiv}, R_{xv}, R_{xvi}, R_{xvii}, and R_{xviii} are each independently alkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, aryl, arylalkyl, aryl(hydroxy)alkyl, aryloxyalkyl, arylcarbonyl, arylthioalkyl, carboxy, carboxyalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, halogen, heteroaryl, heteroarylalkyl, heterocycle, heterocyclealkyl, heterocyclecarbonyl, hydroxyalkyl, trialkylsilylalkyl, $H_2NC(O)$-alkyl, Z_aZ_bN-, Z_aZ_bNalkyl, $Z_cZ_dNC(O)$- or $Z_cZ_dNS(O)_2$-;

Z_a and Z_b are each independently hydrogen, alkyl, alkoxycarbonylalkyl, aryl, arylalkyl, cycloalkyl, $H_2NC(O)$-, H_2NalkylC(O)-, $H_2NC(O)$-alkyl, dialkylNC(O)- or dialkylNC(O)-alkyl-;

Z_c and Z_d are each independently hydrogen, alkyl, alkoxyalkyl, aryl, arylalkyl, aryl(hydroxy)alkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycle, heterocyclealkyl, hydroxyalkyl, $H_2NC(O)$-alkyl-, dialkylNC(O)-alkyl-, dialkylN-alkyl-, or CHZ_eZ_f;

Z_e is aryl or heteroaryl;

Z_f is heteroarylalkyl, heterocyclealkyl, or Z_1Z_2N-alkyl-;

m is 0, 1 or 2;

a is 0 or 1;

b is 0, 1, or 2;


c is 0, 1, 2 or 3; and

d is 0, 1, 2, 3 or 4.

2. The compound according to claim 1, wherein

A is (ii), (iii), (iv), (vii), (x), (xiv), (xv), (xvi), (xvii), or (xviii).

3. The compound according to claim 2, wherein A is (ii)



(ii);

R_2 is hydrogen, alkoxycarbonyl, heterocyclecarbonyl, alkylcarbonyl, or R_eR_fN-alkyl-C(O)-;

R_4 is alkyl, alkoxyalkyl, aryl, cycloalkyl, heterocycle, heterocyclealkyl, R_jR_kN- or R_jR_kN-alkyl-;

R_5 is alkyl, aryl or heteroaryl;

R_e and R_f are each independently hydrogen or alkyl;

R_j and R_k are each independently hydrogen, alkyl, aryl, cycloalkyl, or heterocycle;

R_{ii} is alkyl, alkoxyalkyl, alkoxycarbonyl, aryl, arylalkyl, aryl(hydroxy)alkyl, aryloxyalkyl, arylcarbonyl, alkoxycarbonylalkyl, arylthioalkyl, carboxy, carboxyalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, halogen, heteroaryl, heteroarylalkyl, heterocycle, heterocyclealkyl, heterocyclecarbonyl, hydroxyalkyl, trialkylsilylalkyl, Z_aZ_bN-, Z_aZ_bNalkyl- or $Z_cZ_dNC(O)$-;

Z_a and Z_b are each independently hydrogen, alkyl or H_2NalkylC(O)-;

Z_c and Z_d are each independently hydrogen, alkyl, alkoxyalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, heterocyclealkyl, hydroxyalkyl or dialkylN-alkyl-;

m is 0; and

b is 0, 1, or 2.

4. The compound according to claim 3, wherein

R_2 is hydrogen, alkoxycarbonyl or R_eR_fN-alkyl-C(O)-;

R_4 is alkyl, alkoxyalkyl, aryl, cycloalkyl, heterocycle, heterocyclealkyl, R_jR_kN- or R_jR_kN-alkyl-;

R_5 is alkyl, aryl or heteroaryl;

R_j and R_k are each independently hydrogen, alkyl, aryl cycloalkyl or heterocycle;

R_{ii} is alkyl, alkoxyalkyl, alkoxycarbonylalkyl, aryl, arylalkyl, aryloxyalkyl, arylcarbonyl, arylthioalkyl, carboxy, carboxyalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, halogen, heteroaryl, heteroarylalkyl, heterocyclealkyl, heterocyclecarbonyl, hydroxyalkyl, trialkylsilylalkyl, $Z_aZ_bNalkyl$-, or $Z_cZ_dNC(O)$-;

Z_a and Z_b are each independently hydrogen or alkyl;

Z_c and Z_d are each independently hydrogen, alkyl, alkoxyalkyl, aryl, arylalkyl, cycloalkylalkyl or heterocyclealkyl;

m is 0; and

b is 0, 1 or 2.

5. The compound according to claim 3, wherein

R_2 is hydrogen;

R_4 is alkyl, alkoxyalkyl or aryl;

R_5 is alkyl or aryl;

R_{ii} is alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl or halogen;

b is 1 or 2; and

m is 0.

6. The compound according to claim 3, wherein

R_4 is alkoxyalkyl, alkyl, aryl, or R_jR_kN-;

R_5 is alkyl, aryl, or heteroaryl;

R_j and R_k are alkyl;

R_{ii} is alkyl, alkoxyalkyl, aryl, arylalkyl, aryl(hydroxy)alkyl, aryloxyalkyl, arylcarbonyl, arylthioalkyl, carboxy, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, halogen, heteroaryl, heteroarylalkyl, heterocyclealkyl, heterocyclecarbonyl, hydroxyalkyl, $Z_aZ_bNalkyl$ or $Z_cZ_dNC(O)$-;

Z_a and Z_b are each independently hydrogen or $H_2Nalkyl$-C(O)-;


Z_c and Z_d are each independently hydrogen, alkoxyalkyl, alkyl, arylalkyl,

cycloalkyl, cycloalkylalkyl, or heterocyclealkyl;

b is 1 or 2; and

m is 0.

7. The compound according to claim 2, wherein A is (iii)



(iii);


R_2 is hydrogen;

R_{iii} is arylalkyl;

m is 0; and

c is 1.

8. The compound according to claim 2, wherein A is (iii)



(iii);

R_2 is hydrogen;

R_4 is R_jR_kN-alkyl-;


R_j and R_k are alkyl;

R_{iii} is alkoxycarbonylalkyl, alkyl, arylalkyl, cyanoalkyl, heterocyclealkyl, or $H_2NC(O)$-alkyl-;

c is 0, 1 or 2; and

m is 0.

9. The compound according to claim 2, wherein A is (iv)



(iv);

R_2 is hydrogen;

R_{iv} is alkyl, aryl, arylalkyl, heterocycle, heterocyclealkyl or Z_aZ_bNalkyl or Z_cZ_dNS(O)$_2$-;


Z_a and Z_b are each independently hydrogen or alkyl;

Z_c and Z_d are each alkyl;

c is 0, or 1; and

m is 0.

10. The compound according to claim 2, wherein A is (vii)



(vii);

R_2 is hydrogen;

R_{vii} is alkyl, alkoxycarbonyl, aryl, arylalkyl, cycloalkyl, heterocyclealkyl, heterocyclecarbonyl, hydroxyalkyl or Z_cZ_dNC(O)-;

Z_c and Z_d are each independently hydrogen, alkyl, alkoxyalkyl, aryl, arylalkyl, aryl(hydroxy)alkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycle, heterocyclealkyl, hydroxyalkyl, or CHZ_eZ_f;


Z_e is aryl or heteroaryl;

Z_f is heteroarylalkyl, heterocyclealkyl, or Z_1Z_2N-alkyl-;

b is 1; and

m is 0.

11. The compound according to claim 2, wherein A is (vii)



(vii)

R_2 is hydrogen;


R_{vii} is alkyl, alkoxycarbonyl, arylalkyl, cycloalkyl, heterocyclealkyl, heterocyclecarbonyl, hydroxyalkyl or $Z_cZ_dNC(O)$-;

Z_c and Z_d are each independently hydrogen, alkyl, alkoxyalkyl, aryl, arylalkyl, aryl(hydroxy)alkyl, cycloalkyl, heteroarylalkyl, heterocyclealkyl or hydroxyalkyl;

b is 1; and

m is 0.

12. The compound according to claim 2, wherein A is (vii)



(vii);


R_2 is hydrogen;

R_{vii} is alkyl or arylalkyl;

b is 1; and

m is 0.

13. The compound according to claim 2, wherein A is (x)



(x);

R_1 is hydrogen;

R_2 is hydrogen;


R_x is alkyl, aryl or Z_aZ_bN-;

Z_a and Z_b are each independently hydrogen, alkyl, aryl or arylalkyl;

b is 1 or 2; and

m is 0.

14. The compound according to claim 2, wherein A is (xiv)



(xiv);

R_1 is hydrogen;

R_2 is hydrogen;


R_{xiv} is Z_aZ_bN-;

Z_a and Z_b are each independently hydrogen or cycloalkyl;

c is 1; and

m is 0.

15. The compound according to claim 2, wherein A is (xv)



(xv);

R_2 is hydrogen;


R_{xv} is Z_aZ_bN-;

Z_a and Z_b are each independently hydrogen, alkoxycarbonylalkyl, aryl, arylalkyl or cycloalkyl;

d is 0 or 1; and

m is 0.

16. The compound according to claim 2, wherein A is (xvi)



(xvi);

R_1 is hydrogen;

R_2 is hydrogen;


R_{xvi} is Z_aZ_bN-;

Z_a and Z_b are each independently hydrogen or cycloalkyl;

d is 1; and

m is 0.

17. The compound according to claim 2, wherein A is (xvii)



(xvii);

R_1 is hydrogen;

R_2 is hydrogen;


R_{xvii} is Z_aZ_bN- or aryl;

Z_a and Z_b are each independently hydrogen, alkyl, alkoxycarbonylalkyl, aryl, arylalkyl, cycloalkyl, or $H_2NC(O)$-alkyl;

d is 0 or 1; and

m is 0.

18. The compound according to claim 2, wherein A is (xviii)



(xviii);

R_1 is R_aR_bN-;

R_2 is hydrogen;

c is 0; and

m is 0.

19. The compound of claim 1, that is

5-(1-benzyl-1H-1,2,3-triazol-5-yl)-1H-indazole compound with 5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazole;

5-(1H-1,2,3-triazol-5-yl)-1H-indazole;

5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazole;

5-[1-(2-methylbenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(3-methylbenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(3-methoxybenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(2-fluorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(3-fluorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(2-chlorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(3-chlorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(4-chlorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(2-bromobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(2-nitrobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(3-nitrobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(4-nitrobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

2-{[4-(1H-indazol-5-yl)-1H-1,2,3-triazol-1-yl]methyl}benzonitrile;

3-{[4-(1H-indazol-5-yl)-1H-1,2,3-triazol-1-yl]methyl}benzonitrile;

4-{[4-(1H-indazol-5-yl)-1H-1,2,3-triazol-1-yl]methyl}benzonitrile;

5-{1-[2-(trifluoromethyl)benzyl]-1H-1,2,3-triazol-4-yl}-1H-indazole;

5-{1-[3-(trifluoromethyl)benzyl]-1H-1,2,3-triazol-4-yl}-1H-indazole;

5-{1-[4-(trifluoromethyl)benzyl]-1H-1,2,3-triazol-4-yl}-1H-indazole;

5-{1-[3-(trifluoromethoxy)benzyl]-1H-1,2,3-triazol-4-yl}-1H-indazole;

5-{1-[4-(trifluoromethoxy)benzyl]-1H-1,2,3-triazol-4-yl}-1H-indazole;

5-[1-(4-tert-butylbenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

methyl 3-{[4-(1H-indazol-5-yl)-1H-1,2,3-triazol-1-yl]methyl}benzoate;

methyl 4-{[4-(1H-indazol-5-yl)-1H-1,2,3-triazol-1-yl]methyl}benzoate;

5-[1-(2,4-dimethylbenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(3,5-dimethylbenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(2,3-dichlorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(2,4-dichlorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(2,5-dichlorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(3,5-dichlorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-{1-[2,4-bis(trifluoromethyl)benzyl]-1H-1,2,3-triazol-4-yl}-1H-indazole;

N-cyclohexyl-6-(1H-indazol-5-yl)imidazo[2,1-b][1,3]thiazol-5-amine;

N-cyclohexyl-2-(1H-indazol-5-yl)imidazo[1,2-a]pyridin-3-amine;

N-cyclohexyl-2-(1H-indazol-5-yl)imidazo[1,2-a]pyrazin-3-amine;

5-[1-benzyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-1H-indazole;

N-{3-[4-(4-fluorophenyl)-5-(1H-indazol-5-yl)-1H-imidazol-1-yl]propyl}-N,N-dimethylamine;

5-[4-(4-fluorophenyl)-1-(1-phenylethyl)-1H-imidazol-5-yl]-1H-indazole;

4-(1H-indazol-5-yl)-N-phenyl-1,3-thiazol-2-amine;

5-(2-methyl-1,3-thiazol-4-yl)-1H-indazole;

N-ethyl-4-(1H-indazol-5-yl)-1,3-thiazol-2-amine;

N-benzyl-4-(1H-indazol-5-yl)-1,3-thiazol-2-amine;

4-(1H-indazol-5-yl)-1,3-thiazol-2-amine;

4-(1H-indazol-5-yl)-N-(2-phenylethyl)-1,3-thiazol-2-amine;

N-benzyl-2-(1H-indazol-5-yl)imidazo[1,2-a]pyrimidin-3-amine;

N-butyl-2-(1H-indazol-5-yl)imidazo[1,2-a]pyrimidin-3-amine;

N-(4-chlorophenyl)-2-(1H-indazol-5-yl)imidazo[1,2-a]pyrimidin-3-amine;

2-(1H-indazol-5-yl)-N-(4-methoxyphenyl)imidazo[1,2-a]pyrimidin-3-amine;

2-(1H-indazol-5-yl)imidazo[1,2-a]pyrimidine;

methyl N-[2-(1H-indazol-5-yl)imidazo[1,2-a]pyridin-3-yl]glycinate;

N-benzyl-2-(1H-indazol-5-yl)imidazo[1,2-a]pyridin-3-amine;

N-(4-chlorophenyl)-2-(1H-indazol-5-yl)imidazo[1,2-a]pyridin-3-amine;

2-(1H-indazol-5-yl)-N-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3-amine;

tert-butyl 4-[4-(4-fluorophenyl)-5-(1H-indazol-5-yl)-1H-imidazol-1-yl]piperidine-1-carboxylate;

5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-amine;

5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1-[(1-methylpiperidin-4-yl)carbonyl]-1H-

indazol-3-amine;

5-[4-(4-fluorophenyl)-1-piperidin-4-yl-1H-imidazol-5-yl]-1H-indazole;

5-{4-(4-fluorophenyl)-1-[2-(1-methylpyrrolidin-2-yl)ethyl]-1H-imidazol-5-yl}-1H-indazole;

5-{4-(4-fluorophenyl)-1-[3-(4-methylpiperazin-1-yl)propyl]-1H-imidazol-5-yl}-1H-indazole;

ethyl 5-(1H-indazol-5-yl)isoxazole-3-carboxylate;

5-(1H-indazol-5-yl)-N-methylisoxazole-3-carboxamide;

5-(3-benzylisoxazol-5-yl)-1H-indazole;

5-(3-propylisoxazol-5-yl)-1H-indazole;

N-benzyl-4-(1H-indazol-5-yl)-5-phenyl-1,3-thiazol-2-amine;

4-(1H-indazol-5-yl)-N,5-diphenyl-1,3-thiazol-2-amine;

5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazole;

5-(1-benzyl-4-cyclopropyl-1H-1,2,3-triazol-5-yl)-1H-indazole;

2-(1H-indazol-5-yl)-3-phenylimidazo[1,2-a]pyrimidine;

5-[1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[3-(piperidin-1-ylcarbonyl)isoxazol-5-yl]-1H-indazole;

5-(1H-indazol-5-yl)-N-phenylisoxazole-3-carboxamide;

N-cyclohexyl-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-[3-(piperidin-1-ylmethyl)isoxazol-5-yl]-1H-indazole;

[5-(1H-indazol-5-yl)isoxazol-3-yl]methanol;

5-(1H-indazol-5-yl)-N-(2-methoxyethyl)isoxazole-3-carboxamide;

5-(1-benzyl-5-phenyl-1H-1,2,3-triazol-4-yl)-1H-indazole;

5-(4-benzyl-1H-1,2,3-triazol-1-yl)-1H-indazole;

5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-amine;

5-(1-benzyl-4-cyclopropyl-1H-1,2,3-triazol-5-yl)-1H-indazol-3-amine;

5-(3-isobutylisoxazol-5-yl)-1H-indazol-3-amine;

5-(3-benzylisoxazol-5-yl)-1H-indazol-3-amine;

N-{2-[4-(4-fluorophenyl)-5-(1H-indazol-5-yl)-1H-imidazol-1-yl]ethyl}-N,N-dimethylamine;

5-[4-(4-fluorophenyl)-1-(3-morpholin-4-ylpropyl)-1H-imidazol-5-yl]-1H-

indazole;

5-[4-(4-fluorophenyl)-1-(3-pyrrolidin-1-ylpropyl)-1H-imidazol-5-yl]-1H-indazole;

5-{4-(4-fluorophenyl)-1-[2-(4-methylpiperidin-1-yl)ethyl]-1H-imidazol-5-yl}-1H-indazole;

5-[1-(1-benzylpiperidin-4-yl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-1H-indazole;

5-[4-(4-fluorophenyl)-1-(2-morpholin-4-ylethyl)-1H-imidazol-5-yl]-1H-indazole;

5-[1-(1-benzylpyrrolidin-3-yl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-1H-indazole;

2-{4-[4-(4-fluorophenyl)-5-(1H-indazol-5-yl)-1H-imidazol-1-yl]piperidin-1-yl}-2-oxoethanol;

5-(1-benzyl-5-phenyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-amine;

2-[1-(1H-indazol-5-yl)-1H-1,2,3-triazol-4-yl]propan-2-ol;

5-[4-(methoxymethyl)-1H-1,2,3-triazol-1-yl]-1H-indazole;

1-[1-(1H-indazol-5-yl)-1H-1,2,3-triazol-4-yl]-1-phenylethanol;

5-(4-propyl-1H-1,2,3-triazol-1-yl)-1H-indazole;

1-[1-(1H-indazol-5-yl)-1H-1,2,3-triazol-4-yl]propan-2-ol;

3-[1-(1H-indazol-5-yl)-1H-1,2,3-triazol-4-yl]propan-1-ol;

1-{[1-(1H-indazol-5-yl)-1H-1,2,3-triazol-4-yl]methyl}-1H-1,2,3-benzotriazole;

5-{4-[(phenylthio)methyl]-1H-1,2,3-triazol-1-yl}-1H-indazole;

5-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)-1H-indazole;

5-[4-(2-phenylethyl)-1H-1,2,3-triazol-1-yl]-1H-indazole;

5-[4-(cyclohexylmethyl)-1H-1,2,3-triazol-1-yl]-1H-indazole;

5-(4-cyclopentyl-1H-1,2,3-triazol-1-yl)-1H-indazole;

1-[1-(1H-indazol-5-yl)-1H-1,2,3-triazol-4-yl]cyclohexanol;

5-[4-(phenoxymethyl)-1H-1,2,3-triazol-1-yl]-1H-indazole;

5-{4-[(1,1-dioxidothiomorpholin-4-yl)methyl]-1H-1,2,3-triazol-1-yl}-1H-indazole;

5-[4-(3-phenylpropyl)-1H-1,2,3-triazol-1-yl]-1H-indazole;

[1-benzyl-4-(1H-indazol-5-yl)-1H-1,2,3-triazol-5-yl](phenyl)methanone;

N,N-diethyl-N-{[1-(1H-indazol-5-yl)-1H-1,2,3-triazol-4-yl]methyl}amine;

ethyl N-[2-(1H-indazol-5-yl)imidazo[1,2-a]pyrimidin-3-yl]-beta-alaninate;

5-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-1H-indazole;

5-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-amine;

N^3-[2-(1*H*-indazol-5-yl)imidazo[1,2-*a*]pyrimidin-3-yl]-β-alaninamide;

5-(1-benzyl-5-iodo-1H-1,2,3-triazol-4-yl)-1H-indazol-3-amine;

N-{3-[4-(3-amino-1H-indazol-5-yl)-1-benzyl-1H-1,2,3-triazol-5-yl]phenyl}-N'-(3-methylphenyl)urea;

5-(1H-indazol-5-yl)-N-(2-isopropoxyethyl)isoxazole-3-carboxamide;

5-[3-(morpholin-4-ylcarbonyl)isoxazol-5-yl]-1H-indazole;

5-(1H-indazol-5-yl)-N-(3-morpholin-4-ylpropyl)isoxazole-3-carboxamide;

N-[2-(1H-imidazol-4-yl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

(3R)-1-{[5-(1H-indazol-5-yl)isoxazol-3-yl]carbonyl}piperidin-3-ol;

1-{[5-(1H-indazol-5-yl)isoxazol-3-yl]carbonyl}piperidine-3-carboxamide;

2-[2-(4-{[5-(1H-indazol-5-yl)isoxazol-3-yl]carbonyl}piperazin-1-yl)ethoxy]ethanol;

5-{3-[(4-methyl-1,4-diazepan-1-yl)carbonyl]isoxazol-5-yl}-1H-indazole;

N-(3-hydroxypropyl)-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[(1R)-2-hydroxy-1-phenylethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[3-(2-oxopyrrolidin-1-yl)propyl]isoxazole-3-carboxamide;

N-{2-[4-(aminosulfonyl)phenyl]ethyl}-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

[1-benzyl-4-(1H-indazol-5-yl)-1H-1,2,3-triazol-5-yl](3-chlorophenyl)methanone;

[1-benzyl-4-(1H-indazol-5-yl)-1H-1,2,3-triazol-5-yl](cyclopropyl)methanone;

5-[5-cyclopropyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

N^1-{[1-benzyl-4-(1*H*-indazol-5-yl)-1*H*-1,2,3-triazol-5-yl]methyl}glycinamide;

(4-fluorophenyl)[4-(1H-indazol-5-yl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-5-yl]methanone;

(4-chlorophenyl)[4-(1H-indazol-5-yl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-5-yl]methanone;

(3-chlorophenyl)[4-(1H-indazol-5-yl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-5-yl]methanone;

(2-chlorophenyl)[4-(1H-indazol-5-yl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-5-yl]methanone;

cyclopentyl[4-(1H-indazol-5-yl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-5-yl]methanone;

1-benzyl-4-(1H-indazol-5-yl)-1H-1,2,3-triazole-5-carboxylic acid;

5-{5-(4-fluorophenyl)-1-[4-(trifluoromethyl)benzyl]-1H-1,2,3-triazol-4-yl}-1H-indazol-3-amine;

5-[1-benzyl-5-(4-fluorophenyl)-1H-1,2,3-triazol-4-yl]-1H-indazol-3-amine;

[4-(1H-indazol-5-yl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-5-yl](tetrahydro-2H-pyran-4-yl)methanone;

5-[1-benzyl-5-(2-methylphenyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-{1-benzyl-5-[(4-methylpiperazin-1-yl)carbonyl]-1H-1,2,3-triazol-4-yl}-1H-indazole;

1-{[1-benzyl-4-(1H-indazol-5-yl)-1H-1,2,3-triazol-5-yl]carbonyl}piperidin-4-ol;

1-acetyl-5-[5-(4-fluorophenyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

1-benzyl-4-(1H-indazol-5-yl)-N,N-dimethyl-1H-1,2,3-triazole-5-carboxamide;

N,1-dibenzyl-4-(1H-indazol-5-yl)-1H-1,2,3-triazole-5-carboxamide;

N-(2-hydroxy-2-phenylethyl)-5-(1H-indazol-5-yl)-N-methylisoxazole-3-carboxamide;

N-[(1S)-2-hydroxy-1-phenylethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-benzyl-N-(2-hydroxyethyl)-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-[1-benzyl-5-(2-methylphenyl)-1H-1,2,3-triazol-4-yl]-1H-indazol-3-amine;

2-{2-[1-(1H-indazol-5-yl)-1H-1,2,3-triazol-4-yl]ethyl}-1H-isoindole-1,3(2H)-dione;

5-{4-[(2,4-dichlorophenoxy)methyl]-1H-1,2,3-triazol-1-yl}-1H-indazole;

5-{4-[(2,6-dichlorophenoxy)methyl]-1H-1,2,3-triazol-1-yl}-1H-indazole;

5-[5-(4-fluorophenyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

1-{[1-(1H-indazol-5-yl)-1H-1,2,3-triazol-4-yl]methyl}-1H-indazole;

5-[1-benzyl-5-(piperidin-1-ylcarbonyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[5-(2-methylphenyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[5-(2-methylphenyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-4-yl]-1H-indazol-3-amine;

5-[1-benzyl-5-(morpholin-4-ylcarbonyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-benzyl-5-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl]-1H-indazol-3-amine;

N-[(1S)-1-benzyl-2-hydroxyethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-{3-[(3-phenylmorpholin-4-yl)carbonyl]isoxazol-5-yl}-1H-indazole;

N-benzyl-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

((1S)-2-{[5-(1H-indazol-5-yl)isoxazol-3-yl]carbonyl}-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methanol;

N-[(1R)-3-hydroxy-1-phenylpropyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[(1S)-3-hydroxy-1-phenylpropyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-2,3-dihydro-1H-inden-1-yl-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-2,3-dihydro-1H-inden-2-yl-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(1-phenylpropyl)isoxazole-3-carboxamide;

5-{1-benzyl-5-[3-(dimethylamino)phenyl]-1H-1,2,3-triazol-4-yl}-1H-indazol-3-amine;

5-{1-benzyl-5-[4-(dimethylamino)phenyl]-1H-1,2,3-triazol-4-yl}-1H-indazol-3-amine;

N-{3-[4-(3-amino-1H-indazol-5-yl)-1-benzyl-1H-1,2,3-triazol-5-yl]phenyl}acetamide;

N-{4-[4-(3-amino-1H-indazol-5-yl)-1-benzyl-1H-1,2,3-triazol-5-yl]phenyl}acetamide;

5-{1-benzyl-5-[3-(1H-pyrazol-1-yl)phenyl]-1H-1,2,3-triazol-4-yl}-1H-indazol-3-

amine;

5-[1-benzyl-5-(1-methyl-1H-pyrazol-4-yl)-1H-1,2,3-triazol-4-yl]-1H-indazol-3-amine;

3-[4-(3-amino-1H-indazol-5-yl)-1-benzyl-1H-1,2,3-triazol-5-yl]-N-phenylbenzamide;

3-[4-(3-amino-1H-indazol-5-yl)-1-benzyl-1H-1,2,3-triazol-5-yl]-N-benzylbenzamide;

5-[1-benzyl-5-(1-methyl-1H-indol-5-yl)-1H-1,2,3-triazol-4-yl]-1H-indazol-3-amine;

5-[1-benzyl-5-(3-methoxyphenyl)-1H-1,2,3-triazol-4-yl]-1H-indazol-3-amine;

5-[1-benzyl-5-(3-morpholin-4-ylphenyl)-1H-1,2,3-triazol-4-yl]-1H-indazol-3-amine;

5-[3-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)isoxazol-5-yl]-1H-indazole;

5-{3-[(4-methyl-2-phenylpiperazin-1-yl)carbonyl]isoxazol-5-yl}-1H-indazole;

1-{[1-benzyl-4-(1H-indazol-5-yl)-1H-1,2,3-triazol-5-yl]carbonyl}piperidin-4-amine;

N-[(1R)-1-benzyl-2-hydroxyethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1-benzyl-1H-pyrazol-4-yl)-1H-indazole;

3-[4-(3-amino-1H-indazol-5-yl)-1-benzyl-1H-1,2,3-triazol-5-yl]phenol;

3-[4-(3-amino-1H-indazol-5-yl)-1-benzyl-1H-1,2,3-triazol-5-yl]benzamide;

5-{1-benzyl-5-[4-(methylsulfonyl)phenyl]-1H-1,2,3-triazol-4-yl}-1H-indazol-3-amine;

5-(1H-indazol-5-yl)-N-[(1S)-1-phenylpropyl]isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1R)-1-phenylpropyl]isoxazole-3-carboxamide;

5-(1-benzyl-1H-pyrazol-4-yl)-1H-indazol-3-amine;

1-benzyl-4-(1H-indazol-5-yl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-4-(1H-indazol-5-yl)-N-(2-isopropoxyethyl)-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-4-(1H-indazol-5-yl)-N-[(2R)-tetrahydrofuran-2-ylmethyl]-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-4-(1H-indazol-5-yl)-N-(tetrahydrofuran-3-ylmethyl)-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-N-cyclopentyl-4-(1H-indazol-5-yl)-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-N-(cyclopentylmethyl)-4-(1H-indazol-5-yl)-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-N-ethyl-4-(1H-indazol-5-yl)-N-methyl-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-4-(1H-indazol-5-yl)-N-isopropyl-N-methyl-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-4-(1H-indazol-5-yl)-N-(2-methoxyethyl)-N-methyl-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-4-(1H-indazol-5-yl)-N-phenyl-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-N-(4-chlorophenyl)-4-(1H-indazol-5-yl)-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-4-(1H-indazol-5-yl)-N-(2-morpholin-4-ylethyl)-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-N-[2-(dimethylamino)ethyl]-4-(1H-indazol-5-yl)-N-methyl-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-N-(2-hydroxyethyl)-4-(1H-indazol-5-yl)-N-propyl-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-N-[3-(dimethylamino)propyl]-4-(1H-indazol-5-yl)-N-methyl-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-N-[2-(diethylamino)ethyl]-4-(1H-indazol-5-yl)-N-methyl-1H-1,2,3-triazole-5-carboxamide;

N,1-dibenzyl-N-ethyl-4-(1H-indazol-5-yl)-1H-1,2,3-triazole-5-carboxamide;

N,1-dibenzyl-N-(2-hydroxyethyl)-4-(1H-indazol-5-yl)-1H-1,2,3-triazole-5-carboxamide;

(3R)-1-{[1-benzyl-4-(1H-indazol-5-yl)-1H-1,2,3-triazol-5-yl]carbonyl}piperidin-3-ol;

1-{[1-benzyl-4-(1H-indazol-5-yl)-1H-1,2,3-triazol-5-yl]carbonyl}piperidine-4-carboxamide;

5-{1-benzyl-5-[(2,6-dimethylmorpholin-4-yl)carbonyl]-1H-1,2,3-triazol-4-yl}-1H-indazole;

5-{5-[(4-acetylpiperazin-1-yl)carbonyl]-1-benzyl-1H-1,2,3-triazol-4-yl}-1H-indazole;

5-{1-benzyl-5-[(4-phenylpiperazin-1-yl)carbonyl]-1H-1,2,3-triazol-4-yl}-1H-indazole;

1-benzyl-N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]-4-(1H-indazol-5-yl)-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-4-(1H-indazol-5-yl)-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-N-[3-(1H-imidazol-1-yl)propyl]-4-(1H-indazol-5-yl)-1H-1,2,3-triazole-5-carboxamide;

3-[4-(3-amino-1H-indazol-5-yl)-1H-pyrazol-1-yl]propanenitrile;

2-[4-(3-amino-1H-indazol-5-yl)-1H-pyrazol-1-yl]acetamide;

methyl 3-[4-(3-amino-1H-indazol-5-yl)-1H-pyrazol-1-yl]propanoate;

3-[4-(3-amino-1H-indazol-5-yl)-1H-pyrazol-1-yl]propanamide;

[4-(3-amino-1H-indazol-5-yl)-1H-pyrazol-1-yl]acetonitrile;

4-(3-amino-1H-indazol-5-yl)-N,N-dimethyl-1H-imidazole-1-sulfonamide;

5-imidazo[1,2-a]pyridin-3-yl-1H-indazol-3-amine;

5-(1H-pyrazol-5-yl)-1H-indazol-3-amine;

5-(4-methyl-1H-imidazol-5-yl)-1H-indazol-3-amine;

5-(1H-imidazol-4-yl)-1H-indazol-3-amine;

N-3,4-dihydro-1H-isochromen-4-yl-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-(cyclohexylmethyl)-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-(3-chlorobenzyl)-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(2-methoxybenzyl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[2-(trifluoromethyl)benzyl]isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[3-(trifluoromethyl)benzyl]isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[4-(trifluoromethyl)benzyl]isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(pyridin-2-ylmethyl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(pyridin-3-ylmethyl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(pyridin-4-ylmethyl)isoxazole-3-carboxamide;

N-(2-chlorobenzyl)-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-(4-chlorobenzyl)-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(1-phenyl-2-piperidin-1-ylethyl)isoxazole-3-carboxamide;

N-[2-(1H-imidazol-1-yl)-1-phenylethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(2-morpholin-4-yl-1-phenylethyl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[2-(4-methylpiperazin-1-yl)-1-phenylethyl]isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(1-phenyl-2-pyrrolidin-1-ylethyl)isoxazole-3-carboxamide;

tert-butyl 2-({[5-(1H-indazol-5-yl)isoxazol-3-yl]carbonyl}amino)-2-phenylethylcarbamate;

5-(1H-indazol-5-yl)-N-(1-naphthylmethyl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(2-phenylethyl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(2-pyridin-2-ylethyl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(2-pyridin-3-ylethyl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(2-pyridin-4-ylethyl)isoxazole-3-carboxamide;

N-[2-(2-chlorophenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[2-(3-chlorophenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[2-(4-chlorophenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-benzyl-N-ethyl-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-methyl-N-(1-naphthylmethyl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-methyl-N-(2-phenylethyl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-methyl-N-(2-pyridin-2-ylethyl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1R)-1-phenylethyl]isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-1,2,3,4-tetrahydronaphthalen-1-ylisoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1S)-1-(1-naphthyl)ethyl]isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1R)-1-(1-naphthyl)ethyl]isoxazole-3-carboxamide;

N-[3-(dimethylamino)-1-phenylpropyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-(2,3-dihydro-1,4-benzodioxin-5-ylmethyl)-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-(3,4-dihydro-2H-1,5-benzodioxepin-6-ylmethyl)-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1-methyl-1H-indol-4-yl)methyl]isoxazole-3-carboxamide;

5-{3-[(3-phenylpyrrolidin-1-yl)carbonyl]isoxazol-5-yl}-1H-indazole;

5-{3-[(2-phenylpyrrolidin-1-yl)carbonyl]isoxazol-5-yl}-1H-indazole;

5-{3-[(2-phenylpiperidin-1-yl)carbonyl]isoxazol-5-yl}-1H-indazole;

5-(1H-indazol-5-yl)-N-[(1S)-1-phenylethyl]isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1R)-1-(4-methylphenyl)ethyl]isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1S)-1-(4-methylphenyl)ethyl]isoxazole-3-carboxamide;

N-[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[(1R,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[(1R)-1-(4-bromophenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[(1S)-1-(4-bromophenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[(1R)-1-(4-chlorophenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[(1S)-1-(4-chlorophenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1S)-1-(2-naphthyl)ethyl]isoxazole-3-carboxamide;

N-[1-(4-ethoxyphenyl)-2-hydroxyethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[2-hydroxy-1-(4-isopropylphenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[1-(3,4-dimethylphenyl)-2-hydroxyethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[2-hydroxy-1-(2-methoxyphenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[2-hydroxy-1-(4-methylphenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1R)-1-(2-methoxyphenyl)ethyl]isoxazole-3-carboxamide;

N-[(1S)-1-(3,4-difluorophenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1R)-1-(3-methoxyphenyl)ethyl]isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-{(1R)-1-[3-(trifluoromethyl)phenyl]ethyl}isoxazole-3-carboxamide;

N-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[1-(3,5-dichlorophenyl)-2-hydroxyethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1-benzyl-1*H*-1,2,3-triazol-4-yl)-1-[(1-methylpiperidin-2-yl)carbonyl]-1*H*-indazol-3-amine;


5-(1-benzyl-1*H*-1,2,3-triazol-4-yl)-1-[(dimethylamino)acetyl]-1*H*-indazol-3-amine; and

tert-butyl 3-amino-5-(1-benzyl-1*H*-1,2,3-triazol-4-yl)-1*H*-indazole-1-carboxylate;

20. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) according to claim 1, in combination with a pharmaceutically suitable carrier.

What is claimed is


1. A compound of formula (I)




(I),

or a pharmaceutically acceptable salt thereof, wherein


A is




(i), (ii), (iii), (iv), (v)




(vi), (vii), (viii), (ix)




(x), (xi), (xii), (xiii)



(xiv), (xv), (xvi), (xvii)



(xviii), (xix), (xx), (xxi)



(xxii) or (xxiii);

R_1 is hydrogen, alkyl, aryl, heterocycle, heteroaryl, R_aR_bN-, R_cR_dN-C(O)- or

N-[3-(dimethylamino)-1-phenylpropyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-(2,3-dihydro-1,4-benzodioxin-5-ylmethyl)-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-(3,4-dihydro-2H-1,5-benzodioxepin-6-ylmethyl)-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1-methyl-1H-indol-4-yl)methyl]isoxazole-3-carboxamide;

5-{3-[(3-phenylpyrrolidin-1-yl)carbonyl]isoxazol-5-yl}-1H-indazole;

5-{3-[(2-phenylpyrrolidin-1-yl)carbonyl]isoxazol-5-yl}-1H-indazole;

5-{3-[(2-phenylpiperidin-1-yl)carbonyl]isoxazol-5-yl}-1H-indazole;

5-(1H-indazol-5-yl)-N-[(1S)-1-phenylethyl]isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1R)-1-(4-methylphenyl)ethyl]isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1S)-1-(4-methylphenyl)ethyl]isoxazole-3-carboxamide;

N-[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[(1R,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[(1R)-1-(4-bromophenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[(1S)-1-(4-bromophenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[(1R)-1-(4-chlorophenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[(1S)-1-(4-chlorophenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1S)-1-(2-naphthyl)ethyl]isoxazole-3-carboxamide;

N-[1-(4-ethoxyphenyl)-2-hydroxyethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[2-hydroxy-1-(4-isopropylphenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[1-(3,4-dimethylphenyl)-2-hydroxyethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[2-hydroxy-1-(2-methoxyphenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[2-hydroxy-1-(4-methylphenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1R)-1-(2-methoxyphenyl)ethyl]isoxazole-3-carboxamide;

N-[(1S)-1-(3,4-difluorophenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1R)-1-(3-methoxyphenyl)ethyl]isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-{(1R)-1-[3-(trifluoromethyl)phenyl]ethyl}isoxazole-3-carboxamide;

N-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[1-(3,5-dichlorophenyl)-2-hydroxyethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1-benzyl-1*H*-1,2,3-triazol-4-yl)-1-[(1-methylpiperidin-2-yl)carbonyl]-1*H*-indazol-3-amine;


5-(1-benzyl-1*H*-1,2,3-triazol-4-yl)-1-[(dimethylamino)acetyl]-1*H*-indazol-3-amine; and

tert-butyl 3-amino-5-(1-benzyl-1*H*-1,2,3-triazol-4-yl)-1*H*-indazole-1-carboxylate;

20. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) according to claim 1, in combination with a pharmaceutically suitable carrier.

What is claimed is


1. A compound of formula (I)





(I),

or a pharmaceutically acceptable salt thereof, wherein


A is



(i)



(ii)


(iii)



(iv)



(v)



(vi)



(vii)



(viii)



(ix)



(x)



(xi)



(xii)



(xiii)



(xiv)



(xv)



(xvi)



(xvii)


(xviii)



(xix)


(xx)


(xxi)


(xxii)

or


(xxiii);

R_1 is hydrogen, alkyl, aryl, heterocycle, heteroaryl, R_aR_bN-, R_cR_dN-C(O)- or

R_cR_dN-$S(O)_2$-;

R_2 is hydrogen, alkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, heterocyclecarbonyl or R_eR_fN-alkyl–C(O)-;

R_3 is alkyl, alkoxy, aryl, cyano, cycloalkyl, halogen, haloalkyl, heteroaryl, nitro, or R_gR_hN-;

R_4 is alkyl, alkoxyalkyl, aryl, cycloalkyl, heteroaryl, heterocycle, heterocycloalkyl, R_jR_kN- or R_jR_kN-alkyl-;

R_5 is alkyl, aryl, or heteroaryl;

R_6 is alkyl, alkoxyalkyl, R_jR_kN-alkyl-, aryl, cycloalkyl or heteroaryl;

R_7 is alkyl, aryl or heteroaryl;

R_a and R_b are each independently hydrogen, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, R_4-C(O)-, or R_5-$S(O)_2$-;

R_c and R_d are each independently hydrogen, alkyl or heteroaryl;

R_e and R_f are each independently hydrogen, alkyl, arylalkyl, heteroarylalkyl, R_6-C(O)-, or R_7-$S(O)_2$-;

R_g and R_h are each independently hydrogen, alkyl, or alkylcarbonyl;

R_j and R_k are each independently hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl, or heterocycle;

R_i, R_{ii}, R_{iii}, R_{iv}, R_v, R_{vi}, R_{vii}, R_{viii}, R_{ix}, R_x, R_{xi}, R_{xii}, R_{xiii}, R_{xiv}, R_{xv}, R_{xvi}, R_{xvii}, R_{xviii}, R_{xix}, R_{xx}, R_{xxi}, R_{xxii}, and R_{xxiii} are each independently alkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, aryl, arylalkyl, aryl(hydroxy)alkyl, aryloxyalkyl, arylcarbonyl, arylthioalkyl, carboxy, carboxyalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, halogen, heteroaryl, heteroarylalkyl, heterocycle, heterocyclealkyl, heterocyclecarbonyl, hydroxyalkyl, trialkylsilylalkyl, $H_2NC(O)$-alkyl, Z_aZ_bN-, Z_aZ_bNalkyl, $Z_cZ_dNC(O)$- or $Z_cZ_dNS(O)_2$-, wherein R_{xiv}, R_{xv}, R_{xvi}, and R_{xvii} may occur at any open valence on compounds (xiv), (xv), (xvi) or (xvii);

Z_a and Z_b are each independently hydrogen, alkyl, alkoxycarbonylalkyl, aryl, arylalkyl, cycloalkyl, $H_2NC(O)$-, H_2NalkylC(O)-, $H_2NC(O)$-alkyl, dialkylNC(O)- or dialkylNC(O)-alkyl-;

Z_c and Z_d are each independently hydrogen, alkyl, alkoxyalkyl, aryl, arylalkyl, aryl(hydroxy)alkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycle, heterocyclealkyl, hydroxyalkyl, $H_2NC(O)$-alkyl-, dialkylNC(O)-alkyl-, dialkylN-alkyl-, or CHZ_eZ_f;

Z_e is aryl or heteroaryl;

Z_f is heteroarylalkyl, heterocyclealkyl, or Z_1Z_2N-alkyl-;

m is 0, 1 or 2;

a is 0 or 1;

b is 0, 1, or 2;


c is 0, 1, 2 or 3; and

d is 0, 1, 2, 3 or 4.

2. The compound according to claim 1, wherein

A is (ii), (iii), (iv), (vii), (x), (xiv), (xv), (xvi), (xvii), (xviii), (xix), (xx), (xxi), (xxii), or (xxiii).

3. The compound according to claim 2, wherein A is (ii)



(ii);

R_1 is hydrogen, aryl, heteroaryl, heterocycle, R_aR_bN-, or R_cR_dN-C(O)-;

R_2 is hydrogen, alkoxycarbonyl, heterocyclecarbonyl, alkylcarbonyl, or R_eR_fN-alkyl-C(O)-;

R_4 is alkyl, alkoxyalkyl, aryl, cycloalkyl, heterocycle, heterocyclealkyl, R_jR_kN- or R_jR_kN-alkyl-;

R_5 is alkyl, aryl or heteroaryl;

R_a and R_b are each independently hydrogen, arylalkyl, cycloalkylalkyl, R_4-C(O)- or R_5-$S(O)_2$-;

R_c and R_d are each independently hydrogen or heteroaryl;

R_e and R_f are each independently hydrogen or alkyl;

R_j and R_k are each independently hydrogen, alkyl, aryl, cycloalkyl, or heterocycle;

R_{ii} is alkyl, alkoxyalkyl, alkoxycarbonyl, aryl, arylalkyl, aryl(hydroxy)alkyl, aryloxyalkyl, arylcarbonyl, alkoxycarbonylalkyl, arylthioalkyl, carboxy, carboxyalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, halogen, heteroaryl, heteroarylalkyl, heterocycle, heterocyclealkyl, heterocyclecarbonyl, hydroxyalkyl, trialkylsilylalkyl, Z_aZ_bN-, $Z_aZ_bN$alkyl- or $Z_cZ_dNC(O)$-;

Z_a and Z_b are each independently hydrogen, alkyl or H_2NalkylC(O)-;

Z_c and Z_d are each independently hydrogen, alkyl, alkoxyalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, heterocyclealkyl, hydroxyalkyl or dialkylN-alkyl-;

m is 0; and

b is 0, 1, or 2.

4. The compound according to claim 3, wherein

R_1 is hydrogen, heterocycle, R_aR_bN-, or R_cR_dN-C(O)-;

R_2 is hydrogen, alkoxycarbonyl or R_eR_fN-alkyl-C(O)-;

R_4 is alkyl, alkoxyalkyl, aryl, cycloalkyl, heterocycle, heterocyclealkyl, R_jR_kN- or R_jR_kN-alkyl-;

R_5 is alkyl, aryl or heteroaryl;

R_a and R_b are each independently hydrogen, arylalkyl, cycloalkylalkyl, R_4-C(O)- or R_5-$S(O)_2$-;

R_j and R_k are each independently hydrogen, alkyl, aryl cycloalkyl or heterocycle;

R_{ii} is alkyl, alkoxyalkyl, alkoxycarbonylalkyl, aryl, arylalkyl, aryloxyalkyl, arylcarbonyl, arylthioalkyl, carboxy, carboxyalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, halogen, heteroaryl, heteroarylalkyl, heterocyclealkyl, heterocyclecarbonyl, hydroxyalkyl, trialkylsilylalkyl, $Z_aZ_bN$alkyl-, or $Z_cZ_dNC(O)$-;

Z_a and Z_b are each independently hydrogen or alkyl;

Z_c and Z_d are each independently hydrogen, alkyl, alkoxyalkyl, aryl, arylalkyl, cycloalkylalkyl or heterocyclealkyl;

m is 0; and

b is 0, 1 or 2.

5. The method according to claim 3, wherein

R_1 is hydrogen or R_aR_bN-;

R_2 is hydrogen;

R_4 is alkyl, alkoxyalkyl or aryl;

R_5 is alkyl or aryl;

R_a and R_b are each independently hydrogen, arylalkyl, R_4-C(O)- or R_5-$S(O)_2$-;

R_{ii} is alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl or halogen;

b is 1 or 2; and

m is 0.

6. The method according to claim 3, wherein

R_1 is hydrogen, aryl, heteroaryl or R_aR_bN-, wherein the heteroaryl is triazole substituted with arylalkyl;

R_4 is alkoxyalkyl, alkyl, aryl, or R_jR_kN-;

R_5 is alkyl, aryl, or heteroaryl;

R_a and R_b are each independently hydrogen, arylalkyl, R_4-C(O)-, or R_5-S(O)$_2$-;

R_j and R_k are alkyl;

R_{ii} is alkyl, alkoxyalkyl, aryl, arylalkyl, aryl(hydroxy)alkyl, aryloxyalkyl, arylcarbonyl, arylthioalkyl, carboxy, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, halogen, heteroaryl, heteroarylalkyl, heterocyclealkyl, heterocyclecarbonyl, hydroxyalkyl, $Z_aZ_bN$alkyl or $Z_cZ_dNC(O)$-;

Z_a and Z_b are each independently hydrogen or H_2Nalkyl-C(O)-;

Z_c and Z_d are each independently hydrogen, alkoxyalkyl, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, or heterocyclealkyl;

b is 1 or 2; and

m is 0.

7. The compound according to claim 2, wherein A is (iii)



(iii);

R_1 is hydrogen or R_aR_bN-;

R_2 is hydrogen;


R_a and R_b are each hydrogen;

R_{iii} is arylalkyl;

m is 0; and

c is 1.

8. The compound according to claim 2, wherein A is (iii)



(iii);

R_1 is hydrogen or R_aR_bN-;

R_2 is hydrogen;

R_4 is R_jR_kN-alkyl-;

R_a and R_b are each independently hydrogen, or R_4-C(O)-;


R_j and R_k are alkyl;

R_{iii} is alkoxycarbonylalkyl, alkyl, arylalkyl, cyanoalkyl, heterocyclealkyl, or $H_2NC(O)$-alkyl-;

c is 0, 1 or 2; and

m is 0.

9. The compound according to claim 2, wherein A is (iv)



(iv);

R_1 is hydrogen or R_aR_bN-;

R_2 is hydrogen;

R_a and R_b are each hydrogen;

R_{iv} is alkyl, aryl, arylalkyl, heterocycle, heterocyclealkyl or $Z_aZ_bN$alkyl or $Z_cZ_dNS(O)_2$-;


Z_a and Z_b are each independently hydrogen or alkyl;

Z_c and Z_d are each alkyl;

c is 0, or 1; and

m is 0.

10. The compound according to claim 2, wherein A is (vii)



(vii);

R_1 is hydrogen,–NR_aR_b, or alkyl;

R_2 is hydrogen;

R_a and R_b are each hydrogen;

R_{vii} is alkyl, alkoxycarbonyl, aryl, arylalkyl, cycloalkyl, heterocyclealkyl, heterocyclecarbonyl, hydroxyalkyl or $Z_cZ_dNC(O)$-;

Z_c and Z_d are each independently hydrogen, alkyl, alkoxyalkyl, aryl, arylalkyl, aryl(hydroxy)alkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycle, heterocyclealkyl, hydroxyalkyl, or CHZ_eZ_f;


Z_e is aryl or heteroaryl;

Z_f is heteroarylalkyl, heterocyclealkyl, or Z_1Z_2N-alkyl-;

b is 1; and

m is 0.

11. The compound according to claim 2, wherein A is (vii)



(vii)

R_1 is hydrogen, alkyl, or R_aR_bN-;

R_2 is hydrogen;

R_a and R_b are each hydrogen;


R_{vii} is alkyl, alkoxycarbonyl, arylalkyl, cycloalkyl, heterocyclealkyl, heterocyclecarbonyl, hydroxyalkyl or $Z_cZ_dNC(O)$-;

Z_c and Z_d are each independently hydrogen, alkyl, alkoxyalkyl, aryl, arylalkyl, aryl(hydroxy)alkyl, cycloalkyl, heteroarylalkyl, heterocyclealkyl or hydroxyalkyl;

b is 1; and

m is 0.

12. The method according to claim 2, wherein A is (vii)



(vii);

R_1 is hydrogen or R_aR_bN-;

R_2 is hydrogen;


R_a and R_b are hydrogen;

R_{vii} is alkyl or arylalkyl;

b is 1; and

m is 0.

13. The compound according to claim 2, wherein A is (x)



(x);

R_1 is hydrogen;

R_2 is hydrogen;


R_x is alkyl, aryl or Z_aZ_bN-;

Z_a and Z_b are each independently hydrogen, alkyl, aryl or arylalkyl;

b is 1 or 2; and

m is 0.

14. The compound according to claim 2, wherein A is (xiv)



(xiv);

R_1 is hydrogen;

R_2 is hydrogen;


R_{xiv} is Z_aZ_bN-;

Z_a and Z_b are each independently hydrogen or cycloalkyl;

c is 1; and

m is 0.

15. The compound according to claim 2, wherein A is (xv)



(xv);

R_1 is hydrogen or R_aR_bN-;

R_2 is hydrogen;

R_a and R_b are hydrogen;


R_{xv} is Z_aZ_bN-;

Z_a and Z_b are each independently hydrogen, alkoxycarbonylalkyl, aryl, arylalkyl or cycloalkyl;

d is 0 or 1; and

m is 0.

16. The compound according to claim 2, wherein A is (xvi)



(xvi);

R_1 is hydrogen;

R_2 is hydrogen;


R_{xvi} is Z_aZ_bN-;

Z_a and Z_b are each independently hydrogen or cycloalkyl;

d is 1; and

m is 0.

17. The compound according to claim 2, wherein A is (xvii)



(xvii);

R_1 is hydrogen;

R_2 is hydrogen;


R_{xvii} is Z_aZ_bN- or aryl;

Z_a and Z_b are each independently hydrogen, alkyl, alkoxycarbonylalkyl, aryl, arylalkyl, cycloalkyl, or $H_2NC(O)$-alkyl;

d is 0 or 1; and

m is 0.

18. The compound according to claim 2, wherein A is (xviii)



(xviii);

R_1 is R_aR_bN-;


R_2 is hydrogen;

R_a and R_b are each hydrogen;

c is 0; and

m is 0.

19. The compound according to claim 2, wherein A is (xix)



(xix);

R_1 is R_aR_bN-;


R_2 is hydrogen;

R_a and R_b are each hydrogen;

c is 0; and

m is 0.

20. The compound according to claim 2, wherein A is (xx)



(xx);

R_1 is R_aR_bN-;

R_2 is hydrogen;

R_4 is R_jR_kN-alkyl-;

R_a and R_b are each independently hydrogen or R_4-C(O)-;

R_j and R_k are independently alkyl;


R_{xx} is Z_aZ_bN- or heterocycle;

Z_a and Z_b are each independently hydrogen or alkyl;

c is 0 or 1; and

m is 0.

21. The compound according to claim 2, wherein A is (xxi)



(xxi);

R_1 is R_aR_bN-;

R_2 is hydrogen;


R_a and R_b are each hydrogen;

R_{xxi} is alkoxy;

d is 1; and

m is 0.

22. The compound according to claim 2, wherein A is (xxii)



(xxii);

R_1 is R_aR_bN-;

R_2 is hydrogen;

R_4 is R_jR_kN-alkyl-;


R_a and R_b are each independently hydrogen or R_4-C(O)-;

R_j and R_k are each independently alkyl;

c is 0; and

m is 0.

23. The compound according to claim 2, wherein A is (xxiii)



(xxiii);

R_1 is R_aR_bN-;

R_2 is hydrogen;

R_a and R_b are each hydrogen;

c is 0; and

m is 0.

24. The compound of claim 1, that is

5-(1-benzyl-1H-1,2,3-triazol-5-yl)-1H-indazole compound with 5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazole;

5-(1H-1,2,3-triazol-5-yl)-1H-indazole;

5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazole;

5-[1-(2-methylbenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(3-methylbenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(3-methoxybenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(2-fluorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(3-fluorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(2-chlorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(3-chlorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(4-chlorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(2-bromobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(2-nitrobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(3-nitrobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(4-nitrobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

2-{[4-(1H-indazol-5-yl)-1H-1,2,3-triazol-1-yl]methyl}benzonitrile;

3-{[4-(1H-indazol-5-yl)-1H-1,2,3-triazol-1-yl]methyl}benzonitrile;

4-{[4-(1H-indazol-5-yl)-1H-1,2,3-triazol-1-yl]methyl}benzonitrile;

5-{1-[2-(trifluoromethyl)benzyl]-1H-1,2,3-triazol-4-yl}-1H-indazole;

5-{1-[3-(trifluoromethyl)benzyl]-1H-1,2,3-triazol-4-yl}-1H-indazole;

5-{1-[4-(trifluoromethyl)benzyl]-1H-1,2,3-triazol-4-yl}-1H-indazole;

5-{1-[2-(trifluoromethoxy)benzyl]-1H-1,2,3-triazol-4-yl}-1H-indazole;

5-{1-[4-(trifluoromethoxy)benzyl]-1H-1,2,3-triazol-4-yl}-1H-indazole;

5-[1-(4-tert-butylbenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

methyl 3-{[4-(1H-indazol-5-yl)-1H-1,2,3-triazol-1-yl]methyl}benzoate;

methyl 4-{[4-(1H-indazol-5-yl)-1H-1,2,3-triazol-1-yl]methyl}benzoate;

5-[1-(2,4-dimethylbenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(3,5-dimethylbenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(2,3-dichlorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(2,4-dichlorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(2,5-dichlorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-(3,5-dichlorobenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-{1-[2,4-bis(trifluoromethyl)benzyl]-1H-1,2,3-triazol-4-yl}-1H-indazole;

N-cyclohexyl-6-(1H-indazol-5-yl)imidazo[2,1-b][1,3]thiazol-5-amine;

N-cyclohexyl-2-(1H-indazol-5-yl)imidazo[1,2-a]pyridin-3-amine;

N-cyclohexyl-2-(1H-indazol-5-yl)imidazo[1,2-a]pyrazin-3-amine;

5-[1-benzyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-1H-indazole;

N-{3-[4-(4-fluorophenyl)-5-(1H-indazol-5-yl)-1H-imidazol-1-yl]propyl}-N,N-dimethylamine;

N-cyclohexyl-2-(1H-indazol-5-yl)imidazo[1,2-a]pyrimidin-3-amine;

5-[4-(4-fluorophenyl)-1-(1-phenylethyl)-1H-imidazol-5-yl]-1H-indazole;

2-(1H-indazol-5-yl)-N-isopropylimidazo[1,2-a]pyrimidin-3-amine;

4-(1H-indazol-5-yl)-N-phenyl-1,3-thiazol-2-amine;

5-(2-methyl-1,3-thiazol-4-yl)-1H-indazole;

N-ethyl-4-(1H-indazol-5-yl)-1,3-thiazol-2-amine;

N-benzyl-4-(1H-indazol-5-yl)-1,3-thiazol-2-amine;

4-(1H-indazol-5-yl)-1,3-thiazol-2-amine;

4-(1H-indazol-5-yl)-N-(2-phenylethyl)-1,3-thiazol-2-amine;

N-benzyl-2-(1H-indazol-5-yl)imidazo[1,2-a]pyrimidin-3-amine;

N-butyl-2-(1H-indazol-5-yl)imidazo[1,2-a]pyrimidin-3-amine;

N-(4-chlorophenyl)-2-(1H-indazol-5-yl)imidazo[1,2-a]pyrimidin-3-amine;

2-(1H-indazol-5-yl)-N-(4-methoxyphenyl)imidazo[1,2-a]pyrimidin-3-amine;

2-(1H-indazol-5-yl)imidazo[1,2-a]pyrimidine;

methyl N-[2-(1H-indazol-5-yl)imidazo[1,2-a]pyridin-3-yl]glycinate;

N-benzyl-2-(1H-indazol-5-yl)imidazo[1,2-a]pyridin-3-amine;

N-(4-chlorophenyl)-2-(1H-indazol-5-yl)imidazo[1,2-a]pyridin-3-amine;

2-(1H-indazol-5-yl)-N-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3-amine;

tert-butyl 4-[4-(4-fluorophenyl)-5-(1H-indazol-5-yl)-1H-imidazol-1-yl]piperidine-1-carboxylate;

3,5-bis(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazole;

5-(1-benzyl-1H-1,2,3-triazol-4-yl)-3-phenyl-1H-indazole;

5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-amine;

5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1-[(1-methylpiperidin-4-yl)carbonyl]-1H-indazol-3-amine;

N-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-2-methoxyacetamide;

N^1-[5-(1-benzyl-1*H*-1,2,3-triazol-4-yl)-1*H*-indazol-3-yl]-N^2,N^2-dimethylglycinamide;

N-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]butanamide;

5-[4-(4-fluorophenyl)-1-piperidin-4-yl-1H-imidazol-5-yl]-1H-indazole;

5-{4-(4-fluorophenyl)-1-[2-(1-methylpyrrolidin-2-yl)ethyl]-1H-imidazol-5-yl}-1H-indazole;

5-{4-(4-fluorophenyl)-1-[3-(4-methylpiperazin-1-yl)propyl]-1H-imidazol-5-yl}-1H-indazole;

ethyl 5-(1H-indazol-5-yl)isoxazole-3-carboxylate;

5-(1H-indazol-5-yl)-N-methylisoxazole-3-carboxamide;

5-(3-benzylisoxazol-5-yl)-1H-indazole;

N-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]benzamide;

5-(3-propylisoxazol-5-yl)-1H-indazole;

N-benzyl-4-(1H-indazol-5-yl)-5-phenyl-1,3-thiazol-2-amine;

4-(1H-indazol-5-yl)-N,5-diphenyl-1,3-thiazol-2-amine;

5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazole;

5-(1-benzyl-4-cyclopropyl-1H-1,2,3-triazol-5-yl)-1H-indazole;

2-(1H-indazol-5-yl)-3-phenylimidazo[1,2-a]pyrimidine;

5-[1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[3-(piperidin-1-ylcarbonyl)isoxazol-5-yl]-1H-indazole;

5-(1H-indazol-5-yl)-N-phenylisoxazole-3-carboxamide;

N-cyclohexyl-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-[3-(piperidin-1-ylmethyl)isoxazol-5-yl]-1H-indazole;

[5-(1H-indazol-5-yl)isoxazol-3-yl]methanol;

5-(1H-indazol-5-yl)-N-(2-methoxyethyl)isoxazole-3-carboxamide;

5-(1-benzyl-5-phenyl-1H-1,2,3-triazol-4-yl)-1H-indazole;

5-(4-benzyl-1H-1,2,3-triazol-1-yl)-1H-indazole;

5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-amine;

5-(1-benzyl-4-cyclopropyl-1H-1,2,3-triazol-5-yl)-1H-indazol-3-amine;

5-(3-isobutylisoxazol-5-yl)-1H-indazol-3-amine;

5-(3-benzylisoxazol-5-yl)-1H-indazol-3-amine;

N-{2-[4-(4-fluorophenyl)-5-(1H-indazol-5-yl)-1H-imidazol-1-yl]ethyl}-N,N-dimethylamine;

5-[4-(4-fluorophenyl)-1-(3-morpholin-4-ylpropyl)-1H-imidazol-5-yl]-1H-indazole;

5-[4-(4-fluorophenyl)-1-(3-pyrrolidin-1-ylpropyl)-1H-imidazol-5-yl]-1H-indazole;

5-{4-(4-fluorophenyl)-1-[2-(4-methylpiperidin-1-yl)ethyl]-1H-imidazol-5-yl}-1H-indazole;

5-[1-(1-benzylpiperidin-4-yl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-1H-indazole;

5-[4-(4-fluorophenyl)-1-(2-morpholin-4-ylethyl)-1H-imidazol-5-yl]-1H-indazole;

5-[1-(1-benzylpyrrolidin-3-yl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-1H-indazole;

2-{4-[4-(4-fluorophenyl)-5-(1H-indazol-5-yl)-1H-imidazol-1-yl]piperidin-1-yl}-2-oxoethanol;

5-(1-benzyl-5-phenyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-amine;

2-[1-(1H-indazol-5-yl)-1H-1,2,3-triazol-4-yl]propan-2-ol;

5-[4-(methoxymethyl)-1H-1,2,3-triazol-1-yl]-1H-indazole;

1-[1-(1H-indazol-5-yl)-1H-1,2,3-triazol-4-yl]-1-phenylethanol;

5-(4-propyl-1H-1,2,3-triazol-1-yl)-1H-indazole;

1-[1-(1H-indazol-5-yl)-1H-1,2,3-triazol-4-yl]propan-2-ol;

3-[1-(1H-indazol-5-yl)-1H-1,2,3-triazol-4-yl]propan-1-ol;

1-{[1-(1H-indazol-5-yl)-1H-1,2,3-triazol-4-yl]methyl}-1H-1,2,3-benzotriazole;

5-{4-[(phenylthio)methyl]-1H-1,2,3-triazol-1-yl}-1H-indazole;

5-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)-1H-indazole;

5-[4-(2-phenylethyl)-1H-1,2,3-triazol-1-yl]-1H-indazole;

5-[4-(cyclohexylmethyl)-1H-1,2,3-triazol-1-yl]-1H-indazole;

5-(4-cyclopentyl-1H-1,2,3-triazol-1-yl)-1H-indazole;

1-[1-(1H-indazol-5-yl)-1H-1,2,3-triazol-4-yl]cyclohexanol;

5-[4-(phenoxymethyl)-1H-1,2,3-triazol-1-yl]-1H-indazole;

5-{4-[(1,1-dioxidothiomorpholin-4-yl)methyl]-1H-1,2,3-triazol-1-yl}-1H-indazole;

5-[4-(3-phenylpropyl)-1H-1,2,3-triazol-1-yl]-1H-indazole;

[1-benzyl-4-(1H-indazol-5-yl)-1H-1,2,3-triazol-5-yl](phenyl)methanone;

N,N-diethyl-N-{[1-(1H-indazol-5-yl)-1H-1,2,3-triazol-4-yl]methyl}amine;

ethyl N-[2-(1H-indazol-5-yl)imidazo[1,2-a]pyrimidin-3-yl]-beta-alaninate;

5-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-1H-indazole;

5-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-amine;

N^3-[2-(1*H*-indazol-5-yl)imidazo[1,2-*a*]pyrimidin-3-yl]-β-alaninamide;

5-(1-benzyl-5-iodo-1H-1,2,3-triazol-4-yl)-1H-indazol-3-amine;

N-{3-[4-(3-amino-1H-indazol-5-yl)-1-benzyl-1H-1,2,3-triazol-5-yl]phenyl}-N'-(3-methylphenyl)urea;

5-(1H-indazol-5-yl)-N-(2-isopropoxyethyl)isoxazole-3-carboxamide;

5-[3-(morpholin-4-ylcarbonyl)isoxazol-5-yl]-1H-indazole;

5-(1H-indazol-5-yl)-N-(3-morpholin-4-ylpropyl)isoxazole-3-carboxamide;

N-[2-(1H-imidazol-4-yl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

(3R)-1-{[5-(1H-indazol-5-yl)isoxazol-3-yl]carbonyl}piperidin-3-ol;

1-{[5-(1H-indazol-5-yl)isoxazol-3-yl]carbonyl}piperidine-3-carboxamide;

2-[2-(4-{[5-(1H-indazol-5-yl)isoxazol-3-yl]carbonyl}piperazin-1-yl)ethoxy]ethanol;

5-{3-[(4-methyl-1,4-diazepan-1-yl)carbonyl]isoxazol-5-yl}-1H-indazole;

N-(3-hydroxypropyl)-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[(1R)-2-hydroxy-1-phenylethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[3-(1H-imidazol-1-yl)propyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[3-(2-oxopyrrolidin-1-yl)propyl]isoxazole-3-carboxamide;

N-{2-[4-(aminosulfonyl)phenyl]ethyl}-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

[1-benzyl-4-(1H-indazol-5-yl)-1H-1,2,3-triazol-5-yl](3-chlorophenyl)methanone;

[1-benzyl-4-(1H-indazol-5-yl)-1H-1,2,3-triazol-5-yl](cyclopropyl)methanone;

5-[5-cyclopropyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

N^1-{[1-benzyl-4-(1*H*-indazol-5-yl)-1*H*-1,2,3-triazol-5-yl]methyl}glycinamide;

(4-fluorophenyl)[4-(1H-indazol-5-yl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-5-yl]methanone;

(4-chlorophenyl)[4-(1H-indazol-5-yl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-5-yl]methanone;

(3-chlorophenyl)[4-(1H-indazol-5-yl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-5-yl]methanone;

(2-chlorophenyl)[4-(1H-indazol-5-yl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-5-yl]methanone;

cyclopentyl[4-(1H-indazol-5-yl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-5-yl]methanone;

1-benzyl-4-(1H-indazol-5-yl)-1H-1,2,3-triazole-5-carboxylic acid;

5-{5-(4-fluorophenyl)-1-[4-(trifluoromethyl)benzyl]-1H-1,2,3-triazol-4-yl}-1H-indazol-3-amine;

5-[1-benzyl-5-(4-fluorophenyl)-1H-1,2,3-triazol-4-yl]-1H-indazol-3-amine;

[4-(1H-indazol-5-yl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-5-yl](tetrahydro-2H-pyran-4-yl)methanone;

5-[1-benzyl-5-(2-methylphenyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-{1-benzyl-5-[(4-methylpiperazin-1-yl)carbonyl]-1H-1,2,3-triazol-4-yl}-1H-indazole;

1-{[1-benzyl-4-(1H-indazol-5-yl)-1H-1,2,3-triazol-5-yl]carbonyl}piperidin-4-ol;

1-acetyl-5-[5-(4-fluorophenyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

1-benzyl-4-(1H-indazol-5-yl)-N,N-dimethyl-1H-1,2,3-triazole-5-carboxamide;

N,1-dibenzyl-4-(1H-indazol-5-yl)-1H-1,2,3-triazole-5-carboxamide;

N-(2-hydroxy-2-phenylethyl)-5-(1H-indazol-5-yl)-N-methylisoxazole-3-carboxamide;

N-[(1S)-2-hydroxy-1-phenylethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-benzyl-N-(2-hydroxyethyl)-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-[1-benzyl-5-(2-methylphenyl)-1H-1,2,3-triazol-4-yl]-3-methyl-1H-indazole;

5-[1-benzyl-5-(2-methylphenyl)-1H-1,2,3-triazol-4-yl]-1H-indazol-3-amine;

2-{2-[1-(1H-indazol-5-yl)-1H-1,2,3-triazol-4-yl]ethyl}-1H-isoindole-1,3(2H)-dione;

5-{4-[(2,4-dichlorophenoxy)methyl]-1H-1,2,3-triazol-1-yl}-1H-indazole;

5-{4-[(2,6-dichlorophenoxy)methyl]-1H-1,2,3-triazol-1-yl}-1H-indazole;

5-[5-(4-fluorophenyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

1-{[1-(1H-indazol-5-yl)-1H-1,2,3-triazol-4-yl]methyl}-1H-indazole;

5-[1-benzyl-5-(piperidin-1-ylcarbonyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[5-(2-methylphenyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[5-(2-methylphenyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-1,2,3-triazol-4-yl]-1H-indazol-3-amine;

5-[1-benzyl-5-(morpholin-4-ylcarbonyl)-1H-1,2,3-triazol-4-yl]-1H-indazole;

5-[1-benzyl-5-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl]-1H-indazol-3-amine;

N-[(1S)-1-benzyl-2-hydroxyethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-{3-[(3-phenylmorpholin-4-yl)carbonyl]isoxazol-5-yl}-1H-indazole;

N-benzyl-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

((1S)-2-{[5-(1H-indazol-5-yl)isoxazol-3-yl]carbonyl}-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methanol;

N-[(1R)-3-hydroxy-1-phenylpropyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[(1S)-3-hydroxy-1-phenylpropyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-2,3-dihydro-1H-inden-1-yl-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-2,3-dihydro-1H-inden-2-yl-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(1-phenylpropyl)isoxazole-3-carboxamide;

5-{1-benzyl-5-[3-(dimethylamino)phenyl]-1H-1,2,3-triazol-4-yl}-1H-indazol-3-amine;

5-{1-benzyl-5-[4-(dimethylamino)phenyl]-1H-1,2,3-triazol-4-yl}-1H-indazol-3-amine;

N-{3-[4-(3-amino-1H-indazol-5-yl)-1-benzyl-1H-1,2,3-triazol-5-yl]phenyl}acetamide;

N-{4-[4-(3-amino-1H-indazol-5-yl)-1-benzyl-1H-1,2,3-triazol-5-yl]phenyl}acetamide;

5-{1-benzyl-5-[3-(1H-pyrazol-1-yl)phenyl]-1H-1,2,3-triazol-4-yl}-1H-indazol-3-amine;

5-[1-benzyl-5-(1-methyl-1H-pyrazol-4-yl)-1H-1,2,3-triazol-4-yl]-1H-indazol-3-amine;

3-[4-(3-amino-1H-indazol-5-yl)-1-benzyl-1H-1,2,3-triazol-5-yl]-N-phenylbenzamide;

3-[4-(3-amino-1H-indazol-5-yl)-1-benzyl-1H-1,2,3-triazol-5-yl]-N-benzylbenzamide;

5-[1-benzyl-5-(1-methyl-1H-indol-5-yl)-1H-1,2,3-triazol-4-yl]-1H-indazol-3-amine;

5-[1-benzyl-5-(3-methoxyphenyl)-1H-1,2,3-triazol-4-yl]-1H-indazol-3-amine;

5-[1-benzyl-5-(3-morpholin-4-ylphenyl)-1H-1,2,3-triazol-4-yl]-1H-indazol-3-amine;

5-[3-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)isoxazol-5-yl]-1H-indazole;

5-{3-[(4-methyl-2-phenylpiperazin-1-yl)carbonyl]isoxazol-5-yl}-1H-indazole;

1-{[1-benzyl-4-(1H-indazol-5-yl)-1H-1,2,3-triazol-5-yl]carbonyl}piperidin-4-amine;

N-[5-(1-benzyl-5-phenyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]benzamide;

N-[5-(1-benzyl-5-phenyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]benzenesulfonamide;

N-[5-(1-benzyl-5-phenyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-N'-(4-methoxyphenyl)urea;

N-[5-(1-benzyl-5-phenyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]butanamide;

N-[5-(1-benzyl-5-phenyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-2-methylpropanamide;

N-[5-(1-benzyl-5-phenyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]cyclopropanecarboxamide;

N-[1-benzoyl-5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]benzamide;

N-[5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-3-fluorobenzamide;

N-[5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]benzamide;

N-benzyl-5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-amine;

N-[(1R)-1-benzyl-2-hydroxyethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1-benzyl-1H-pyrazol-4-yl)-1H-indazole;

N-[(1R)-3-hydroxy-1-phenylpropyl]-5-(3-methyl-1H-indazol-5-yl)isoxazole-3-carboxamide;

3-[4-(3-amino-1H-indazol-5-yl)-1-benzyl-1H-1,2,3-triazol-5-yl]phenol;

3-[4-(3-amino-1H-indazol-5-yl)-1-benzyl-1H-1,2,3-triazol-5-yl]benzamide;

5-{1-benzyl-5-[4-(methylsulfonyl)phenyl]-1H-1,2,3-triazol-4-yl}-1H-indazol-3-amine;

N-[5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-2-chlorobenzamide;

N-[5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-4-chlorobenzamide;

N-[5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]ethanesulfonamide;

N-[5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]benzenesulfonamide;

N-[5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-2-chlorobenzenesulfonamide;

N-[5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-3-chlorobenzenesulfonamide;

N-[5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-4-chlorobenzenesulfonamide;

N-[5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-2,5-dimethylfuran-3-sulfonamide;

5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-N-(2-chlorobenzyl)-1H-indazol-3-amine;

5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-N-(3-chlorobenzyl)-1H-indazol-3-amine;

N-[5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-3-chlorobenzamide;

N-[5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-2-furamide;

5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-N-ethyl-1H-indazol-3-amine;

5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-N-(4-chlorobenzyl)-1H-indazol-3-amine;

5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-N-(3-furylmethyl)-1H-indazol-3-amine;

N-[5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-N'-[5-methyl-2-(trifluoromethyl)-3-furyl]urea;

N-[5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-3-furamide;

5-(1H-indazol-5-yl)-N-[(1S)-1-phenylpropyl]isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1R)-1-phenylpropyl]isoxazole-3-carboxamide;

5-(1-benzyl-1H-pyrazol-4-yl)-1H-indazol-3-amine;

1-benzyl-4-(1H-indazol-5-yl)-N-[(2S)-tetrahydrofuran-2-ylmethyl]-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-4-(1H-indazol-5-yl)-N-(2-isopropoxyethyl)-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-4-(1H-indazol-5-yl)-N-[(2R)-tetrahydrofuran-2-ylmethyl]-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-4-(1H-indazol-5-yl)-N-(tetrahydrofuran-3-ylmethyl)-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-N-cyclopentyl-4-(1H-indazol-5-yl)-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-N-(cyclopentylmethyl)-4-(1H-indazol-5-yl)-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-N-ethyl-4-(1H-indazol-5-yl)-N-methyl-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-4-(1H-indazol-5-yl)-N-isopropyl-N-methyl-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-4-(1H-indazol-5-yl)-N-(2-methoxyethyl)-N-methyl-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-4-(1H-indazol-5-yl)-N-phenyl-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-N-(4-chlorophenyl)-4-(1H-indazol-5-yl)-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-4-(1H-indazol-5-yl)-N-(2-morpholin-4-ylethyl)-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-N-[2-(dimethylamino)ethyl]-4-(1H-indazol-5-yl)-N-methyl-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-N-(2-hydroxyethyl)-4-(1H-indazol-5-yl)-N-propyl-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-N-[3-(dimethylamino)propyl]-4-(1H-indazol-5-yl)-N-methyl-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-N-[2-(diethylamino)ethyl]-4-(1H-indazol-5-yl)-N-methyl-1H-1,2,3-triazole-5-carboxamide;

N,1-dibenzyl-N-ethyl-4-(1H-indazol-5-yl)-1H-1,2,3-triazole-5-carboxamide;

N,1-dibenzyl-N-(2-hydroxyethyl)-4-(1H-indazol-5-yl)-1H-1,2,3-triazole-5-carboxamide;

(3R)-1-{[1-benzyl-4-(1H-indazol-5-yl)-1H-1,2,3-triazol-5-yl]carbonyl}piperidin-3-ol;

1-{[1-benzyl-4-(1H-indazol-5-yl)-1H-1,2,3-triazol-5-yl]carbonyl}piperidine-4-carboxamide;

5-{1-benzyl-5-[(2,6-dimethylmorpholin-4-yl)carbonyl]-1H-1,2,3-triazol-4-yl}-1H-indazole;

5-{5-[(4-acetylpiperazin-1-yl)carbonyl]-1-benzyl-1H-1,2,3-triazol-4-yl}-1H-indazole;

5-{1-benzyl-5-[(4-phenylpiperazin-1-yl)carbonyl]-1H-1,2,3-triazol-4-yl}-1H-indazole;

1-benzyl-N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]-4-(1H-indazol-5-yl)-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-4-(1H-indazol-5-yl)-1H-1,2,3-triazole-5-carboxamide;

1-benzyl-N-[3-(1H-imidazol-1-yl)propyl]-4-(1H-indazol-5-yl)-1H-1,2,3-triazole-5-carboxamide;

N-[5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-N'-ethylurea;

N-[5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-N'-phenylurea;

N-benzyl-N'-[5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]urea;

N-[5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-N'-(2-chlorophenyl)urea;

N-[5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-N'-(3-chlorophenyl)urea;

N-[5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-N'-(4-chlorophenyl)urea;

N-[5-(1-benzyl-5-iodo-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]benzamide;

3-[4-(3-amino-1H-indazol-5-yl)-1H-pyrazol-1-yl]propanenitrile;

2-[4-(3-amino-1H-indazol-5-yl)-1H-pyrazol-1-yl]acetamide;

methyl 3-[4-(3-amino-1H-indazol-5-yl)-1H-pyrazol-1-yl]propanoate;

3-[4-(3-amino-1H-indazol-5-yl)-1H-pyrazol-1-yl]propanamide;

[4-(3-amino-1H-indazol-5-yl)-1H-pyrazol-1-yl]acetonitrile;

4-(3-amino-1H-indazol-5-yl)-N,N-dimethyl-1H-imidazole-1-sulfonamide;

5-pyrazin-2-yl-1H-indazol-3-amine;

5-thien-2-yl-1H-indazol-3-amine;

5-(2-aminopyrimidin-4-yl)-1H-indazol-3-amine;

5-(2-methoxypyridin-3-yl)-1H-indazol-3-amine;

5-imidazo[1,2-a]pyridin-3-yl-1H-indazol-3-amine;

N^2,N^2-dimethyl-N^1-[5-(1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]glycinamide;

5-(1H-pyrazol-5-yl)-1H-indazol-3-amine;

5-(4-methyl-1H-imidazol-5-yl)-1H-indazol-3-amine;

5-(1H-imidazol-4-yl)-1H-indazol-3-amine;

N^2,N^2-dimethyl-N^1-{5-[1-(3-methylbenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazol-3-yl}glycinamide;

5-(1-benzyl-1H-imidazol-4-yl)-1H-indazol-3-amine;

N^1-{5-[1-(4-tert-butylbenzyl)-1H-1,2,3-triazol-4-yl]-1H-indazol-3-yl}-N^2,N^2-dimethylglycinamide;

N^2,N^2-dimethyl-N^1-{5-[1-(2-piperidin-1-ylethyl)-1H-1,2,3-triazol-4-yl]-1H-indazol-3-yl}glycinamide;

N^2,N^2-dimethyl-N^1-{5-[1-(2-morpholin-4-ylethyl)-1H-1,2,3-triazol-4-yl]-1H-indazol-3-yl}glycinamide;

N^1-(5-{1-[2-(3,5-dimethylisoxazol-4-yl)ethyl]-1H-1,2,3-triazol-4-yl}-1H-indazol-3-yl)-N^2,N^2-dimethylglycinamide;

N^1-(5-{1-[2-(3,5-dimethyl-1H-pyrazol-4-yl)ethyl]-1H-1,2,3-triazol-4-yl}-1H-indazol-3-yl)-N^2,N^2-dimethylglycinamide;

2-(4-{3-[(N,N-dimethylglycyl)amino]-1H-indazol-5-yl}-1H-1,2,3-triazol-1-yl)-2-

methylpropanoic acid;

ethyl (4-{3-[(N,N-dimethylglycyl)amino]-1H-indazol-5-yl}-1H-1,2,3-triazol-1-yl)acetate;

N^2,N^2-dimethyl-N^1-(5-{1-[(trimethylsilyl)methyl]-1H-1,2,3-triazol-4-yl}-1H-indazol-3-yl)glycinamide;

N^1-[5-(3-furyl)-1H-indazol-3-yl]-N^2,N^2-dimethylglycinamide;

N^2,N^2-dimethyl-N^1-[5-(1H-pyrazol-5-yl)-1H-indazol-3-yl]glycinamide;

N^2,N^2-dimethyl-N^1-(5-pyrimidin-5-yl-1H-indazol-3-yl)glycinamide;

N^1-[5-(2,1,3-benzoxadiazol-5-yl)-1H-indazol-3-yl]-N^2,N^2-dimethylglycinamide;

N^2,N^2-dimethyl-N^1-[5-(1H-pyrazol-4-yl)-1H-indazol-3-yl]glycinamide;

N^2,N^2-dimethyl-N^1-[5-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-3-yl]glycinamide;

N^1-[5-(3,5-dimethyl-1H-pyrazol-4-yl)-1H-indazol-3-yl]-N^2,N^2-dimethylglycinamide;

N^1-{5-[2-(dimethylamino)pyrimidin-5-yl]-1H-indazol-3-yl}-N^2,N^2-dimethylglycinamide;

N^2,N^2-dimethyl-N^1-[5-(2-morpholin-4-ylpyrimidin-5-yl)-1H-indazol-3-yl]glycinamide;

N^2,N^2-dimethyl-N^1-{5-[1-(2-morpholin-4-ylethyl)-1H-pyrazol-4-yl]-1H-indazol-3-yl}glycinamide;

N^1-[5-(1-benzyl-5-cyclopropyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-N^2,N^2-dimethylglycinamide;

N^1-[5-(1-benzyl-1H-pyrazol-4-yl)-1H-indazol-3-yl]-N^2,N^2-dimethylglycinamide;

N^1-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-N^2-methylglycinamide;

N-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-2-pyrrolidin-1-ylacetamide;

N^1-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-N^2-cyclopentylglycinamide;

N^1-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-N^2-cyclopropylglycinamide;

N^1-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-N^2-tetrahydro-2H-pyran-4-ylglycinamide;

N-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-2-(3-hydroxypyrrolidin-1-yl)acetamide;

N-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-2-(3-hydroxypiperidin-1-yl)acetamide;

N^1-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-N^3,N^3-dimethyl-beta-alaninamide;

N-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-2-morpholin-4-ylacetamide;

N-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-2-(4-methylpiperazin-1-yl)acetamide;

N-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-2-(3-oxopiperazin-1-yl)acetamide;

N^1-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-N^2-isopropylglycinamide;

N^1-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-N^2-cyclohexylglycinamide;

N-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]acetamide;

N^1-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-N^2-cyclobutylglycinamide;

N-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-N'-propylurea;

N-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]ethanesulfonamide;

5-(1-benzyl-1H-1,2,3-triazol-4-yl)-N-(cyclopropylmethyl)-1H-indazol-3-amine;

N-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-N'-ethylurea;

1-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]pyrrolidin-2-one;

N-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-4-(dimethylamino)butanamide;

N-3,4-dihydro-1H-isochromen-4-yl-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-(cyclohexylmethyl)-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-(3-chlorobenzyl)-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(2-methoxybenzyl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[2-(trifluoromethyl)benzyl]isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[3-(trifluoromethyl)benzyl]isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[4-(trifluoromethyl)benzyl]isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(pyridin-2-ylmethyl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(pyridin-3-ylmethyl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(pyridin-4-ylmethyl)isoxazole-3-carboxamide;

N-(2-chlorobenzyl)-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-(4-chlorobenzyl)-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(1-phenyl-2-piperidin-1-ylethyl)isoxazole-3-carboxamide;

N-[2-(1H-imidazol-1-yl)-1-phenylethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(2-morpholin-4-yl-1-phenylethyl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[2-(4-methylpiperazin-1-yl)-1-phenylethyl]isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(1-phenyl-2-pyrrolidin-1-ylethyl)isoxazole-3-carboxamide;

tert-butyl 2-({[5-(1H-indazol-5-yl)isoxazol-3-yl]carbonyl}amino)-2-phenylethylcarbamate;

5-(1H-indazol-5-yl)-N-(1-naphthylmethyl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(2-phenylethyl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(2-pyridin-2-ylethyl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(2-pyridin-3-ylethyl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-(2-pyridin-4-ylethyl)isoxazole-3-carboxamide;

N-[2-(2-chlorophenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[2-(3-chlorophenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[2-(4-chlorophenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-benzyl-N-ethyl-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-methyl-N-(1-naphthylmethyl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-methyl-N-(2-phenylethyl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-methyl-N-(2-pyridin-2-ylethyl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1R)-1-phenylethyl]isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-1,2,3,4-tetrahydronaphthalen-1-ylisoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1S)-1-(1-naphthyl)ethyl]isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1R)-1-(1-naphthyl)ethyl]isoxazole-3-carboxamide;

N-[3-(dimethylamino)-1-phenylpropyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-(2,3-dihydro-1,4-benzodioxin-5-ylmethyl)-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-(3,4-dihydro-2H-1,5-benzodioxepin-6-ylmethyl)-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1-methyl-1H-indol-4-yl)methyl]isoxazole-3-carboxamide;

5-{3-[(3-phenylpyrrolidin-1-yl)carbonyl]isoxazol-5-yl}-1H-indazole;

5-{3-[(2-phenylpyrrolidin-1-yl)carbonyl]isoxazol-5-yl}-1H-indazole;

5-{3-[(2-phenylpiperidin-1-yl)carbonyl]isoxazol-5-yl}-1H-indazole;

5-(1H-indazol-5-yl)-N-[(1S)-1-phenylethyl]isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1R)-1-(4-methylphenyl)ethyl]isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1S)-1-(4-methylphenyl)ethyl]isoxazole-3-carboxamide;

N-[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[(1R,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[(1R)-1-(4-bromophenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[(1S)-1-(4-bromophenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[(1R)-1-(4-chlorophenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[(1S)-1-(4-chlorophenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1S)-1-(2-naphthyl)ethyl]isoxazole-3-carboxamide;

N-[1-(4-ethoxyphenyl)-2-hydroxyethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[2-hydroxy-1-(4-isopropylphenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[1-(3,4-dimethylphenyl)-2-hydroxyethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[2-hydroxy-1-(2-methoxyphenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[2-hydroxy-1-(4-methylphenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1R)-1-(2-methoxyphenyl)ethyl]isoxazole-3-carboxamide;

N-[(1S)-1-(3,4-difluorophenyl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-[(1R)-1-(3-methoxyphenyl)ethyl]isoxazole-3-carboxamide;

5-(1H-indazol-5-yl)-N-{(1R)-1-[3-(trifluoromethyl)phenyl]ethyl}isoxazole-3-carboxamide;

N-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

N-[1-(3,5-dichlorophenyl)-2-hydroxyethyl]-5-(1H-indazol-5-yl)isoxazole-3-carboxamide;

tert-butyl 5-(1-benzyl-1*H*-1,2,3-triazol-4-yl)-3-[({[6-(trifluoromethyl)pyridin-2-yl]amino}carbonyl)amino]-1*H*-indazole-1-carboxylate;

5-(1-benzyl-1*H*-1,2,3-triazol-4-yl)-1-[(1-methylpiperidin-2-yl)carbonyl]-1*H*-indazol-3-amine;

5-(1-benzyl-1*H*-1,2,3-triazol-4-yl)-1-[(dimethylamino)acetyl]-1*H*-indazol-3-amine;

tert-butyl 3-amino-5-(1-benzyl-1*H*-1,2,3-triazol-4-yl)-1*H*-indazole-1-carboxylate;

N-[5-(1-benzyl-1H-1,2,3-triazol-4-yl)-1H-indazol-3-yl]-2-piperidin-1-ylacetamide;

N-[5-(1-benzyl-1*H*-1,2,3-triazol-4-yl)-1*H*-indazol-3-yl]-2-morpholin-4-ylacetamide;

or

N-[5-(1-benzyl-1*H*-1,2,3-triazol-4-yl)-1*H*-indazol-3-yl]-1-methylpiperidine-2-

carboxamide.

25. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) according to claim 1, in combination with a pharmaceutically suitable carrier.

26. A method of inhibiting Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2 comprising administering a therapeutically effective amount of a compound of Formula (I) according to claim 1.

27. A method of inhibiting GSK-3 kinase comprising administering a therapeutically effective amount of a compound of Formula (I), according to claim **4**, wherein the the inhibition of GSK-3 kinase is useful for the treatment or prevention of diseases or disorders regulated by GSK-3 kinase in a human in need thereof.

28. The method according to Claim **27**, wherein the inhibition of GSK-3 kinase is useful for stimulation of neuroregeneration and the treatment and prevention of neurodegenerative diseases, inflammatory and demyelinating diseases, Alzheimer`s disease, stroke, multiple sclerosis, cognitive and attention deficits associated with Alzheimer's disease, acute and chronic neurodegenerative diseases, dementia, acute stroke and other traumatic injuries, cerebrovascular accidents, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma.

29. The method accord to Claim **28**, wherein the acute and chronic neurodegenerative diseases are Parkinson's disease and tauopathies.

30. The method according to Claim **29**, wherein the tautopathies are frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, and progressive supranuclear palsy.

31. The method according to Claim **28**, wherein the dementia is vascular dementia.

32. The method according to Claim **28**, wherein the cerebrovascular accident is age related macular degeneration.

33. The method according to Claim **27**, wherein the inhibition of GSK-3 kinase is useful for the treatment non-insulin dependent diabetes and obesity, manic depressive illness, schizophrenia, alopecia, cancer, osteoarthritis, rheumatoid arthritis, and osteoporosis.

34. The method according to Claim **33**, wherein the cancer is breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, and virus-induced tumors.

35. A method of inhibiting GSK-3 kinase comprising administering a therapeutically effective amount of a compound of Formula (I), according to claim **8**, wherein the inhibition of GSK-3 kinase is useful for the treatment or prevention of diseases or disorders regulated by GSK-3 kinase in a human in need thereof.

36. The method according to Claim **35**, wherein the inhibition of GSK-3 kinase is useful for stimulation of neuroregeneration and the treatment and prevention of neurodegenerative diseases, inflammatory and demyelinating diseases, Alzheimer`s disease, stroke, multiple sclerosis, cognitive and attention deficits associated with Alzheimer's disease, acute and chronic neurodegenerative diseases, dementia, acute stroke and other traumatic injuries, cerebrovascular accidents, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma.

37. The method accord to Claim **36**, wherein the acute and chronic neurodegenerative diseases are Parkinson's disease and tauopathies.

38. The method according to Claim **37**, wherein the tautopathies are frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, and progressive supranuclear palsy.

39. The method according to Claim **36**, wherein the dementia is vascular dementia.

40. The method according to Claim **36**, wherein the cerebrovascular accident is age related macular degeneration.

41. The method according to Claim **35**, wherein the inhibition of GSK-3 kinase is useful for the treatment non-insulin dependent diabetes and obesity, manic depressive illness,

schizophrenia, alopecia, cancer, osteoarthritis, rheumatoid arthritis, and osteoporosis.

42. The method according to Claim **41**, wherein the cancer is breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, and virus-induced tumors.

43. A method of inhibiting GSK-3 kinase comprising administering a therapeutically effective amount of a compound of Formula (I), according to claim **9**, wherein the the inhibition of GSK-3 kinase is useful for the treatment or prevention of diseases or disorders regulated by GSK-3 kinase in a human in need thereof.

44. The method according to Claim **43**, wherein the inhibition of GSK-3 kinase is useful for stimulation of neuroregeneration and the treatment and prevention of neurodegenerative diseases, inflammatory and demyelinating diseases, Alzheimer's disease, stroke, multiple sclerosis, cognitive and attention deficits associated with Alzheimer's disease, acute and chronic neurodegenerative diseases, dementia, acute stroke and other traumatic injuries, cerebrovascular accidents, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma.

45. The method accord to Claim **44,** wherein the acute and chronic neurodegenerative diseases are Parkinson's disease and tauopathies.

46. The method according to Claim **45**, wherein the tautopathies are frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, and progressive supranuclear palsy.

47. The method according to Claim **44**, wherein the dementia is vascular dementia.

48. The method according to Claim **44**, wherein the cerebrovascular accident is age related macular degeneration.

49. The method according to Claim **43**, wherein the inhibition of GSK-3 kinase is useful for the treatment non-insulin dependent diabetes and obesity, manic depressive illness, schizophrenia, alopecia, cancer, osteoarthritis, rheumatoid arthritis, and osteoporosis.

50. The method according to Claim **49**, wherein the cancer is breast cancer, non-small cell

lung carcinoma, thyroid cancer, T or B-cell leukemia, and virus-induced tumors.

51. A method of inhibiting GSK-3 kinase comprising administering a therapeutically effective amount of a compound of Formula (I), according to claim **11**, wherein the the inhibition of GSK-3 kinase is useful for the treatment or prevention of diseases or disorders regulated by GSK-3 kinase in a human in need thereof.

52. The method according to Claim **51**, wherein the inhibition of GSK-3 kinase is useful for stimulation of neuroregeneration and the treatment and prevention of neurodegenerative diseases, inflammatory and demyelinating diseases, Alzheimer`s disease, stroke, multiple sclerosis, cognitive and attention deficits associated with Alzheimer's disease, acute and chronic neurodegenerative diseases, dementia, acute stroke and other traumatic injuries, cerebrovascular accidents, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma.

53. The method accord to Claim **52,** wherein the acute and chronic neurodegenerative diseases are Parkinson's disease and tauopathies.

54. The method according to Claim **53**, wherein the tautopathies are frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, and progressive supranuclear palsy.

55. The method according to Claim **52**, wherein the dementia is vascular dementia.

56. The method according to Claim **52**, wherein the cerebrovascular accident is age related macular degeneration.

57. The method according to Claim **51**, wherein the inhibition of GSK-3 kinase is useful for the treatment non-insulin dependent diabetes and obesity, manic depressive illness, schizophrenia, alopecia, cancer, osteoarthritis, rheumatoid arthritis, and osteoporosis.

58. The method according to Claim **57**, wherein the cancer is breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, and virus-induced tumors.

59. A method of inhibiting GSK-3 kinase comprising administering a therapeutically

effective amount of a compound of Formula (I), according to claim **14**, wherein the the inhibition of GSK-3 kinase is useful for the treatment or prevention of diseases or disorders regulated by GSK-3 kinase in a human in need thereof.

60. The method according to Claim **59**, wherein the inhibition of GSK-3 kinase is useful for stimulation of neuroregeneration and the treatment and prevention of neurodegenerative diseases, inflammatory and demyelinating diseases, Alzheimer`s disease, stroke, multiple sclerosis, cognitive and attention deficits associated with Alzheimer's disease, acute and chronic neurodegenerative diseases, dementia, acute stroke and other traumatic injuries, cerebrovascular accidents, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma.

61. The method accord to Claim **60,** wherein the acute and chronic neurodegenerative diseases are Parkinson's disease and tauopathies.

62. The method according to Claim **61**, wherein the tauopathies are frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, and progressive supranuclear palsy.

63. The method according to Claim **60**, wherein the dementia is vascular dementia.

64. The method according to Claim **60**, wherein the cerebrovascular accident is age related macular degeneration.

65. The method according to Claim **59**, wherein the inhibition of GSK-3 kinase is useful for the treatment non-insulin dependent diabetes and obesity, manic depressive illness, schizophrenia, alopecia, cancer, osteoarthritis, rheumatoid arthritis, and osteoporosis.

66. The method according to Claim **65**, wherein the cancer is breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, and virus-induced tumors.

67. A method of inhibiting GSK-3 kinase comprising administering a therapeutically effective amount of a compound of Formula (I), according to claim **15**, wherein the the inhibition of GSK-3 kinase is useful for the treatment or prevention of diseases or disorders regulated by GSK-3 kinase in a human in need thereof.

68. The method according to Claim **67**, wherein the inhibition of GSK-3 kinase is useful for stimulation of neuroregeneration and the treatment and prevention of neurodegenerative diseases, inflammatory and demyelinating diseases, Alzheimer`s disease, stroke, multiple sclerosis, cognitive and attention deficits associated with Alzheimer's disease, acute and chronic neurodegenerative diseases, dementia, acute stroke and other traumatic injuries, cerebrovascular accidents, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma.

69. The method accord to Claim **68,** wherein the acute and chronic neurodegenerative diseases are Parkinson's disease and tauopathies.

70. The method according to Claim **69**, wherein the tautopathies are frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, and progressive supranuclear palsy.

71. The method according to Claim **68**, wherein the dementia is vascular dementia.

72. The method according to Claim **68**, wherein the cerebrovascular accident is age related macular degeneration.

73. The method according to Claim **67**, wherein the inhibition of GSK-3 kinase is useful for the treatment non-insulin dependent diabetes and obesity, manic depressive illness, schizophrenia, alopecia, cancer, osteoarthritis, rheumatoid arthritis, and osteoporosis.

74. The method according to Claim **73**, wherein the cancer is breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, and virus-induced tumors.

75. A method of inhibiting GSK-3 kinase comprising administering a therapeutically effective amount of a compound of Formula (I), according to claim **16**, wherein the the inhibition of GSK-3 kinase is useful for the treatment or prevention of diseases or disorders regulated by GSK-3 kinase in a human in need thereof.

76. The method according to Claim **75**, wherein the inhibition of GSK-3 kinase is useful for stimulation of neuroregeneration and the treatment and prevention of neurodegenerative

diseases, inflammatory and demyelinating diseases, Alzheimer`s disease, stroke, multiple sclerosis, cognitive and attention deficits associated with Alzheimer's disease, acute and chronic neurodegenerative diseases, dementia, acute stroke and other traumatic injuries, cerebrovascular accidents, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma.

77. The method accord to Claim **76,** wherein the acute and chronic neurodegenerative diseases are Parkinson's disease and tauopathies.

78. The method according to Claim **77**, wherein the tautopathies are frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, and progressive supranuclear palsy.

79. The method according to Claim **76**, wherein the dementia is vascular dementia.

80. The method according to Claim **76**, wherein the cerebrovascular accident is age related macular degeneration.

81. The method according to Claim **75**, wherein the inhibition of GSK-3 kinase is useful for the treatment non-insulin dependent diabetes and obesity, manic depressive illness, schizophrenia, alopecia, cancer, osteoarthritis, rheumatoid arthritis, and osteoporosis.

82. The method according to Claim **81**, wherein the cancer is breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, and virus-induced tumors.

83. A method of inhibiting GSK-3 kinase comprising administering a therapeutically effective amount of a compound of Formula (I), according to claim **17**, wherein the the inhibition of GSK-3 kinase is useful for the treatment or prevention of diseases or disorders regulated by GSK-3 kinase in a human in need thereof.

84. The method according to Claim **83**, wherein the inhibition of GSK-3 kinase is useful for stimulation of neuroregeneration and the treatment and prevention of neurodegenerative diseases, inflammatory and demyelinating diseases, Alzheimer`s disease, stroke, multiple sclerosis, cognitive and attention deficits associated with Alzheimer's disease, acute and chronic neurodegenerative diseases, dementia, acute stroke and other traumatic injuries,

cerebrovascular accidents, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma.

85. The method accord to Claim **84,** wherein the acute and chronic neurodegenerative diseases are Parkinson's disease and tauopathies.

86. The method according to Claim **85**, wherein the tautopathies are frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, and progressive supranuclear palsy.

87. The method according to Claim **84**, wherein the dementia is vascular dementia.

88. The method according to Claim **84**, wherein the cerebrovascular accident is age related macular degeneration.

89. The method according to Claim **83**, wherein the inhibition of GSK-3 kinase is useful for the treatment non-insulin dependent diabetes and obesity, manic depressive illness, schizophrenia, alopecia, cancer, osteoarthritis, rheumatoid arthritis, and osteoporosis.

90. The method according to Claim **89**, wherein the cancer is breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, and virus-induced tumors.

91. A method of inhibiting GSK-3 kinase comprising administering a therapeutically effective amount of a compound of Formula (I), according to claim **18**, wherein the the inhibition of GSK-3 kinase is useful for the treatment or prevention of diseases or disorders regulated by GSK-3 kinase in a human in need thereof.

92. The method according to Claim **91**, wherein the inhibition of GSK-3 kinase is useful for stimulation of neuroregeneration and the treatment and prevention of neurodegenerative diseases, inflammatory and demyelinating diseases, Alzheimer`s disease, stroke, multiple sclerosis, cognitive and attention deficits associated with Alzheimer's disease, acute and chronic neurodegenerative diseases, dementia, acute stroke and other traumatic injuries, cerebrovascular accidents, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma.

93. The method accord to Claim **92,** wherein the acute and chronic neurodegenerative diseases are Parkinson's disease and tauopathies.

94. The method according to Claim **93**, wherein the tautopathies are frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, and progressive supranuclear palsy.

95. The method according to Claim **92**, wherein the dementia is vascular dementia.

96. The method according to Claim **92**, wherein the cerebrovascular accident is age related macular degeneration.

97. The method according to Claim **91**, wherein the inhibition of GSK-3 kinase is useful for the treatment non-insulin dependent diabetes and obesity, manic depressive illness, schizophrenia, alopecia, cancer, osteoarthritis, rheumatoid arthritis, and osteoporosis.

98. The method according to Claim **97**, wherein the cancer is breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, and virus-induced tumors.

99. A method of inhibiting GSK-3 kinase comprising administering a therapeutically effective amount of a compound of Formula (I), according to claim **19**, wherein the the inhibition of GSK-3 kinase is useful for the treatment or prevention of diseases or disorders regulated by GSK-3 kinase in a human in need thereof.

100. The method according to Claim **99**, wherein the inhibition of GSK-3 kinase is useful for stimulation of neuroregeneration and the treatment and prevention of neurodegenerative diseases, inflammatory and demyelinating diseases, Alzheimer`s disease, stroke, multiple sclerosis, cognitive and attention deficits associated with Alzheimer's disease, acute and chronic neurodegenerative diseases, dementia, acute stroke and other traumatic injuries, cerebrovascular accidents, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma.

101. The method accord to Claim **100,** wherein the acute and chronic neurodegenerative diseases are Parkinson's disease and tauopathies.

102. The method according to Claim **101**, wherein the tautopathies are frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, and progressive supranuclear palsy.

103. The method according to Claim **100**, wherein the dementia is vascular dementia.

104. The method according to Claim **100**, wherein the cerebrovascular accident is age related macular degeneration.

105. The method according to Claim **99**, wherein the inhibition of GSK-3 kinase is useful for the treatment non-insulin dependent diabetes and obesity, manic depressive illness, schizophrenia, alopecia, cancer, osteoarthritis, rheumatoid arthritis, and osteoporosis.

106. The method according to Claim **105**, wherein the cancer is breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, and virus-induced tumors.

107. A method of inhibiting GSK-3 kinase comprising administering a therapeutically effective amount of a compound of Formula (I), according to claim **20**, wherein the the inhibition of GSK-3 kinase is useful for the treatment or prevention of diseases or disorders regulated by GSK-3 kinase in a human in need thereof.

108. The method according to Claim **107**, wherein the inhibition of GSK-3 kinase is useful for stimulation of neuroregeneration and the treatment and prevention of neurodegenerative diseases, inflammatory and demyelinating diseases, Alzheimer`s disease, stroke, multiple sclerosis, cognitive and attention deficits associated with Alzheimer's disease, acute and chronic neurodegenerative diseases, dementia, acute stroke and other traumatic injuries, cerebrovascular accidents, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma.

109. The method accord to Claim **108,** wherein the acute and chronic neurodegenerative diseases are Parkinson's disease and tauopathies.

110. The method according to Claim **109**, wherein the tautopathies are frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, and progressive supranuclear palsy.

111. The method according to Claim **108**, wherein the dementia is vascular dementia.

112. The method according to Claim **108**, wherein the cerebrovascular accident is age related macular degeneration.

113. The method according to Claim **107**, wherein the inhibition of GSK-3 kinase is useful for the treatment non-insulin dependent diabetes and obesity, manic depressive illness, schizophrenia, alopecia, cancer, osteoarthritis, rheumatoid arthritis, and osteoporosis.

114. The method according to Claim **113**, wherein the cancer is breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, and virus-induced tumors.

115. A method of inhibiting GSK-3 kinase comprising administering a therapeutically effective amount of a compound of Formula (I), according to claim **21**, wherein the the inhibition of GSK-3 kinase is useful for the treatment or prevention of diseases or disorders regulated by GSK-3 kinase in a human in need thereof.

116. The method according to Claim **115**, wherein the inhibition of GSK-3 kinase is useful for stimulation of neuroregeneration and the treatment and prevention of neurodegenerative diseases, inflammatory and demyelinating diseases, Alzheimer`s disease, stroke, multiple sclerosis, cognitive and attention deficits associated with Alzheimer's disease, acute and chronic neurodegenerative diseases, dementia, acute stroke and other traumatic injuries, cerebrovascular accidents, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma.

117. The method accord to Claim **116,** wherein the acute and chronic neurodegenerative diseases are Parkinson's disease and tauopathies.

118. The method according to Claim **117**, wherein the tautopathies are frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, and progressive supranuclear palsy.

119. The method according to Claim **116**, wherein the dementia is vascular dementia.

120. The method according to Claim **116**, wherein the cerebrovascular accident is age related

macular degeneration.

121. The method according to Claim **115**, wherein the inhibition of GSK-3 kinase is useful for the treatment non-insulin dependent diabetes and obesity, manic depressive illness, schizophrenia, alopecia, cancer, osteoarthritis, rheumatoid arthritis, and osteoporosis.

122. The method according to Claim **121**, wherein the cancer is breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, and virus-induced tumors.

123. A method of inhibiting GSK-3 kinase comprising administering a therapeutically effective amount of a compound of Formula (I), according to claim **22**, wherein the the inhibition of GSK-3 kinase is useful for the treatment or prevention of diseases or disorders regulated by GSK-3 kinase in a human in need thereof.

124. The method according to Claim **123**, wherein the inhibition of GSK-3 kinase is useful for stimulation of neuroregeneration and the treatment and prevention of neurodegenerative diseases, inflammatory and demyelinating diseases, Alzheimer`s disease, stroke, multiple sclerosis, cognitive and attention deficits associated with Alzheimer's disease, acute and chronic neurodegenerative diseases, dementia, acute stroke and other traumatic injuries, cerebrovascular accidents, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma.

125. The method accord to Claim **124**, wherein the acute and chronic neurodegenerative diseases are Parkinson's disease and tauopathies.

126. The method according to Claim **125**, wherein the tautopathies are frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, and progressive supranuclear palsy.

127. The method according to Claim **124**, wherein the dementia is vascular dementia.

128. The method according to Claim **124**, wherein the cerebrovascular accident is age related macular degeneration.

129. The method according to Claim **123**, wherein the inhibition of GSK-3 kinase is useful

for the treatment non-insulin dependent diabetes and obesity, manic depressive illness, schizophrenia, alopecia, cancer, osteoarthritis, rheumatoid arthritis, and osteoporosis.

130. The method according to Claim **129**, wherein the cancer is breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, and virus-induced tumors.

131. A method of inhibiting GSK-3 kinase comprising administering a therapeutically effective amount of a compound of Formula (I), according to claim **23**, wherein the the inhibition of GSK-3 kinase is useful for the treatment or prevention of diseases or disorders regulated by GSK-3 kinase in a human in need thereof.

132. The method according to Claim **131**, wherein the inhibition of GSK-3 kinase is useful for stimulation of neuroregeneration and the treatment and prevention of neurodegenerative diseases, inflammatory and demyelinating diseases, Alzheimer's disease, stroke, multiple sclerosis, cognitive and attention deficits associated with Alzheimer's disease, acute and chronic neurodegenerative diseases, dementia, acute stroke and other traumatic injuries, cerebrovascular accidents, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma.

133. The method accord to Claim **132,** wherein the acute and chronic neurodegenerative diseases are Parkinson's disease and tauopathies.

134. The method according to Claim **133**, wherein the tautopathies are frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, and progressive supranuclear palsy.

135. The method according to Claim **132**, wherein the dementia is vascular dementia.

136. The method according to Claim **132**, wherein the cerebrovascular accident is age related macular degeneration.

137. The method according to Claim **131**, wherein the inhibition of GSK-3 kinase is useful for the treatment non-insulin dependent diabetes and obesity, manic depressive illness, schizophrenia, alopecia, cancer, osteoarthritis, rheumatoid arthritis, and osteoporosis.

138. The method according to Claim **137**, wherein the cancer is breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, and virus-induced tumors.

139. A method of inhibiting JAK kinase comprising administering a therapeutically effective amount of a compound of Formula (I), according to claim **1** wherein the inhibition of JAK kinase is useful for the treatment or prevention of diseases or disorders regulated by JAK kinases in a human in need thereof.

140. The method according to Claim **139**, wherein the inhibition of JAK kinase is useful for the treatment of autoimmune diseases, myeloproliferative syndromes and cardiovascular diseases associated with abnormal activity of JAK kinases comprises administering to a mammalian organism in need thereof an effective amount of a compound according to claim **5**.

141. The method according to Claim **140,** wherein the myeloproliferative syndromes are leukemias, lymphomas or cancer.

142. The method according to Claim **141**, wherein the cancer is hematologic cancer.

143. The method according to Claim **140,** wherein the autoimmune diseases are rheumatoid arthritis and psoriasis.

144. The method according to Claim **139**, wherein the inhibition of JAK kinase is useful for the treatment of autoimmune diseases, myeloproliferative syndromes and cardiovascular diseases associated with abnormal activity of JAK kinases comprises administering to a mammalian organism in need thereof an effective amount of a compound according to claim **8**.

145. The method according to Claim **144,** wherein the myeloproliferative syndromes are leukemias, lymphomas or cancer.

146. The method according to Claim **145**, wherein the cancer is hematologic cancer.

147. The method according to Claim **144,** wherein the autoimmune diseases are rheumatoid

arthritis and psoriasis.

148. The method according to Claim **139**, wherein the inhibition of JAK kinase is useful for the treatment of autoimmune diseases, myeloproliferative syndromes and cardiovascular diseases associated with abnormal activity of JAK kinases comprises administering to a mammalian organism in need thereof an effective amount of a compound according to claim **12**.

149. The method according to Claim **148,** wherein the myeloproliferative syndromes are leukemias, lymphomas or cancer.

150. The method according to Claim **149**, wherein the cancer is hematologic cancer.

151. The method according to Claim **148,** wherein the autoimmune diseases are rheumatoid arthritis and psoriasis.

152. A method of inhibiting ROCK kinase comprising administering a therapeutically effective amount of a compound of Formula (I), according to claim **3,** wherein the inhibition of ROCK kinase is useful for the treatment of neurodegeneration, inflammatory and demyelinating diseases, Alzheimer`s disease, stroke, pulmonary inflammation associated with asthma, asthma, for accelerated regeneration and enhanced functional recovery after spinal-cord injury, for multiple sclerosis, pain, hypertension, chronic and congestive heart failure, cardiac hypertrophy, restenosis, chronic renal failure, cerebral vasospasm after subarachnoid bleeding, pulmonary hypertension, atherosclerosis, male erectile dysfunctions, female sexual dysfunction, over-active bladder syndrome, induction of new axonal growth, axonal rewiring across lesions within the CNS, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, rheumatoid arthritis, osteoarthritis, irritable bowel syndrome, Crohn's disease, psoriasis, ulcerative colitis, Lupus, cancer and tumor metastasis, anti-viral and anti-bacterial applications, insulin resistance, diabetes, cystic fibrosis, angina pectoris, and arteriosclerosis.

153. A method of inhibiting ROCK kinase comprising administering a therapeutically effective amount of a compound of Formula (I), according to claim **6,** wherein the inhibition of ROCK kinase is useful for the treatment of neurodegeneration, inflammatory and

demyelinating diseases, Alzheimer`s disease, stroke, pulmonary inflammation associated with asthma, asthma, for accelerated regeneration and enhanced functional recovery after spinal-cord injury, for multiple sclerosis, pain, hypertension, chronic and congestive heart failure, cardiac hypertrophy, restenosis, chronic renal failure, cerebral vasospasm after subarachnoid bleeding, pulmonary hypertension, atherosclerosis, male erectile dysfunctions, female sexual dysfunction, over-active bladder syndrome, induction of new axonal growth, axonal rewiring across lesions within the CNS, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, rheumatoid arthritis, osteoarthritis, irritable bowel syndrome, Crohn's disease, psoriasis, ulcerative colitis, Lupus, cancer and tumor metastasis, anti-viral and anti-bacterial applications, insulin resistance, diabetes, cystic fibrosis, angina pectoris, and arteriosclerosis.

154. A method of inhibiting ROCK kinase comprising administering a therapeutically effective amount of a compound of Formula (I), according to claim **7,** wherein the inhibition of ROCK kinase is useful for the treatment of neurodegeneration, inflammatory and demyelinating diseases, Alzheimer`s disease, stroke, pulmonary inflammation associated with asthma, asthma, for accelerated regeneration and enhanced functional recovery after spinal-cord injury, for multiple sclerosis, pain, hypertension, chronic and congestive heart failure, cardiac hypertrophy, restenosis, chronic renal failure, cerebral vasospasm after subarachnoid bleeding, pulmonary hypertension, atherosclerosis, male erectile dysfunctions, female sexual dysfunction, over-active bladder syndrome, induction of new axonal growth, axonal rewiring across lesions within the CNS, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, rheumatoid arthritis, osteoarthritis, irritable bowel syndrome, Crohn's disease, psoriasis, ulcerative colitis, Lupus, cancer and tumor metastasis, anti-viral and anti-bacterial applications, insulin resistance, diabetes, cystic fibrosis, angina pectoris, and arteriosclerosis.

155. A method of inhibiting ROCK kinase comprising administering a therapeutically effective amount of a compound of Formula (I), according to claim **10,** wherein the inhibition of ROCK kinase is useful for the treatment of neurodegeneration, inflammatory and demyelinating diseases, Alzheimer`s disease, stroke, pulmonary inflammation associated with asthma, asthma, for accelerated regeneration and enhanced functional recovery after spinal-cord injury, for multiple sclerosis, pain, hypertension, chronic and congestive heart failure, cardiac hypertrophy, restenosis, chronic renal failure, cerebral vasospasm after

subarachnoid bleeding, pulmonary hypertension, atherosclerosis, male erectile dysfunctions, female sexual dysfunction, over-active bladder syndrome, induction of new axonal growth, axonal rewiring across lesions within the CNS, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, rheumatoid arthritis, osteoarthritis, irritable bowel syndrome, Crohn's disease, psoriasis, ulcerative colitis, Lupus, cancer and tumor metastasis, anti-viral and anti-bacterial applications, insulin resistance, diabetes, cystic fibrosis, angina pectoris, and arteriosclerosis.

156. A method of inhibiting ROCK kinase comprising administering a therapeutically effective amount of a compound of Formula (I), according to claim 13, wherein the inhibition of ROCK kinase is useful for the treatment of neurodegeneration, inflammatory and demyelinating diseases, Alzheimer`s disease, stroke, pulmonary inflammation associated with asthma, asthma, for accelerated regeneration and enhanced functional recovery after spinal-cord injury, for multiple sclerosis, pain, hypertension, chronic and congestive heart failure, cardiac hypertrophy, restenosis, chronic renal failure, cerebral vasospasm after subarachnoid bleeding, pulmonary hypertension, atherosclerosis, male erectile dysfunctions, female sexual dysfunction, over-active bladder syndrome, induction of new axonal growth, axonal rewiring across lesions within the CNS, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, rheumatoid arthritis, osteoarthritis, irritable bowel syndrome, Crohn's disease, psoriasis, ulcerative colitis, Lupus, cancer and tumor metastasis, anti-viral and anti-bacterial applications, insulin resistance, diabetes, cystic fibrosis, angina pectoris, and arteriosclerosis.